<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJL</journal-id>
<journal-id journal-id-type="hwp">spajl</journal-id>
<journal-title>American Journal of Lifestyle Medicine</journal-title>
<issn pub-type="ppub">1559-8276</issn>
<issn pub-type="epub">1559-8284</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1559827612460499</article-id>
<article-id pub-id-type="publisher-id">10.1177_1559827612460499</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Themed Piece</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Ultraviolet Radiation and the Skin</article-title>
<subtitle>An In-Depth Review</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Morganroth</surname><given-names>Pamela A.</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lim</surname><given-names>Henry W.</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Burnett</surname><given-names>Christopher T.</given-names></name>
<degrees>MD</degrees>
</contrib>
<aff id="aff1-1559827612460499">Department of Dermatology, Henry Ford Hospital, Detroit, Michigan</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1559827612460499">Henry W. Lim, MD, Henry Ford Medical Center, New Center One, 3031 West Grand Blvd., Suite 800, Detroit, MI 48230; e-mail: <email>hlim1@hfhs.org</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>168</fpage>
<lpage>181</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>6</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Ultraviolet radiation (UVR) has many interactions with the skin, which are explored in detail in this review. Both ultraviolet A (UVA) and ultraviolet B (UVB) wavelengths are absorbed by chromophores in the skin, resulting in important biologic effects. Exposure to UVR can result in sunburn, immediate and delayed skin pigmentation, photoaging, and immunosuppression. In addition, exposure to UVA and UVB is an important risk factor for melanoma, squamous cell carcinoma, and basal cell carcinoma. Because endogenous vitamin D synthesis requires UVB, concerns have been raised about the possibility that photoprotection might contribute to vitamin D deficiency; however, vitamin D supplementation is a safer and more reliable method for maintaining adequate vitamin D levels than UVR exposure. Protection from UVR is critical and involves several factors. These elements include sun avoidance during peak hours of UVR exposure (10 <sc>am</sc> to 2 <sc>pm</sc>), proper application of a broad-spectrum sunscreen with adequate sun protection factor, and wearing protective clothing, a wide-brimmed hat, and protective eyewear. Indoor tanning is a high-risk activity that is likely contributing to recent increases in melanoma and nonmelanoma skin cancer in young women, and efforts are ongoing to ban minors from engaging in indoor tanning.</p>
</abstract>
<kwd-group>
<kwd>ultraviolet radiation</kwd>
<kwd>skin cancer</kwd>
<kwd>indoor tanning</kwd>
<kwd>sunscreen</kwd>
<kwd>vitamin D</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May/June 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Interactions between ultraviolet radiation (UVR) and the skin are complex and manifold. Certain issues associated with the relationship between UVR and the skin, such as vitamin D deficiency, indoor tanning, sunscreen labeling changes, and the effects of UVR on melanoma incidence, have recently been topics of interest in the media and in medical journals. Other topics, such as nonmelanoma skin cancer, have not garnered as much recent media attention but remain of importance given their common clinical occurrence. This review summarizes many of the most frequently encountered effects of UVR on the skin, including sunburn, pigment alteration, immunosuppression, and nonmelanoma and melanoma skin cancers. The relationship between UVR and vitamin D levels is also reviewed. Last, methods of sun protection and the hazards of indoor tanning are discussed.</p>
<p><disp-quote>
<p>The response of skin to UVR [ultraviolet radiation] varies in patients with different skin colors. . . . Skin type I is the lightest in color and is most susceptible to UV-induced erythema, whereas skin type VI is the darkest and least sensitive to sunburn.</p>
</disp-quote></p>
<sec id="section1-1559827612460499">
<title>Ultraviolet Radiation and Chromophores</title>
<p>Ultraviolet radiation is divided into 3 categories based on wavelength: UVC (270-290 nm), UVB (290-320 nm), and UVA (320-400 nm). UVA is further subdivided into UVA2 (320-340 nm) and UVA1 (340-400 nm). Although all the 3 types of UVR are emitted by the sun, only UVA and UVB reach the earth’s surface, because UVC is absorbed by nitrogen and oxygen molecules in the ozone. At the earth’s surface, UVA is present in much higher quantities than UVB (20:1), and because of its longer wavelength, UVA can penetrate more deeply into the skin than UVB.<sup><xref ref-type="bibr" rid="bibr1-1559827612460499">1</xref></sup> In addition, unlike UVB, most UVA is not filtered by window glass.</p>
<p>For UVR to have a biological effect on the skin, it must be absorbed by molecules in the skin called chromophores. There are many chromophores in the skin, and each absorbs a specific spectrum of electromagnetic wavelengths. Studies have demonstrated that DNA is a major chromophore in human skin for erythema induced by UVB and short UVA wavelengths.<sup><xref ref-type="bibr" rid="bibr2-1559827612460499">2</xref><xref ref-type="bibr" rid="bibr3-1559827612460499"/>-<xref ref-type="bibr" rid="bibr4-1559827612460499">4</xref></sup></p>
<p>The response of skin to UVR varies in patients with different skin colors. Dermatologists frequently classify patients into 1 of 6 skin type categories based on the Fitzpatrick scale. Skin type I is the lightest in color and is most susceptible to UV-induced erythema, whereas skin type VI is the darkest and least sensitive to sunburn. The Fitzpatrick skin types are summarized in <xref ref-type="table" rid="table1-1559827612460499">Table 1</xref>.<sup><xref ref-type="bibr" rid="bibr5-1559827612460499">5</xref></sup></p>
<table-wrap id="table1-1559827612460499" position="float">
<label>Table 1.</label>
<caption>
<p>Fitzpatrick Skin Types.</p>
</caption>
<graphic alternate-form-of="table1-1559827612460499" xlink:href="10.1177_1559827612460499-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Skin Type</th>
<th align="center">Skin Color</th>
<th align="center">Skin Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>White</td>
<td>Always burns, never tans</td>
</tr>
<tr>
<td>II</td>
<td>White</td>
<td>Always burns, tans minimally</td>
</tr>
<tr>
<td>III</td>
<td>White</td>
<td>Burns minimally, tans moderately</td>
</tr>
<tr>
<td>IV</td>
<td>Light brown</td>
<td>Burns minimally, tans well</td>
</tr>
<tr>
<td>V<sup><xref ref-type="table-fn" rid="table-fn1-1559827612460499">a</xref></sup></td>
<td>Brown</td>
<td>Rarely burns, tans deeply</td>
</tr>
<tr>
<td>VI<sup><xref ref-type="table-fn" rid="table-fn1-1559827612460499">a</xref></sup></td>
<td>Dark brown/black</td>
<td>Never burns, tans deeply</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1559827612460499">
<label>a</label>
<p>Determined by physical exam. Other skin types determined predominantly by history.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section2-1559827612460499">
<title>Sunburn</title>
<p>Sunburn manifests clinically as erythema, which is often followed by desquamation. Edema and blisters may occur with more severe sunburns. Erythema typically develops approximately 3 to 5 hours after exposure to the sun, peaks in 12 to 24 hours, and gradually fades over several days.<sup><xref ref-type="bibr" rid="bibr6-1559827612460499">6</xref></sup> However, in individuals with fair skin, immediate erythema may be observed after UVB exposure, and the erythema can last up to 2 weeks.<sup><xref ref-type="bibr" rid="bibr3-1559827612460499">3</xref></sup> It is known that the intensity of erythema resulting from exposure to UVR in the UVA and UVB range (290-400 nm) depends on wavelength, with shorter wavelengths producing erythema more effectively. UVA is separated into UVA2 (320-340 nm) and UVA1 (340-400 nm) because, due to its shorter wavelength, the biologic properties of UVA2 (such as effectiveness at producing erythema) are closer to those of UVB (290-320 nm). Because of the inverse relationship between wavelength and the intensity of erythema generated, solar UVB is the primary cause of sunburn, with UVA2 contributing to a lesser extent. In fact, it has been shown that UVB is 1000 times more erythemogenic than UVA.<sup><xref ref-type="bibr" rid="bibr7-1559827612460499">7</xref></sup></p>
<p>Absorption of UVB by DNA in the skin leads to cyclopyrimidine dimers and pyrimidine pyrimidone photoproducts, which ultimately results in an inflammatory response consisting of vasodilation and increased vascular permeability.<sup><xref ref-type="bibr" rid="bibr8-1559827612460499">8</xref></sup> UVB also causes erythema by increasing prostaglandin E2 synthesis and nitric oxide production.<sup><xref ref-type="bibr" rid="bibr9-1559827612460499">9</xref></sup> Other inflammatory mediators thought to play a role in the sunburn reaction include lipoxygenase products; cytokines, such as tumor necrosis factor–α; adhesion molecules; reactive oxygen radicals; and mast cell–derived mediators, including histamine.<sup><xref ref-type="bibr" rid="bibr10-1559827612460499">10</xref></sup></p>
<p>The most studied medications for sunburn symptoms are nonsteroidal anti-inflammatory drugs (NSAIDs) and topical corticosteroids. Both are mechanistically attractive options because of their anti-inflammatory properties, but studies of these medications have not demonstrated convincing evidence of substantial clinical benefits for sunburn prevention or treatment. Oral and topical NSAIDs have shown mild effectiveness in the prevention and treatment of UVB-induced erythema in clinical trials,<sup><xref ref-type="bibr" rid="bibr10-1559827612460499">10</xref></sup> but the NSAIDs were started before or immediately after UVB exposure in almost all the studies, which limits the clinical applicability. One interesting double-blind randomized controlled trial showed a statistically significant decrease in pain and erythema in the treatment group relative to controls when diclofenac sodium 0.1% gel was administered 6 and 10 hours after exposure to a standardized dose of sunlight,<sup><xref ref-type="bibr" rid="bibr11-1559827612460499">11</xref></sup> but further studies are needed to confirm this result. Although topical corticosteroids are widely used to treat sunburn, there is minimal evidence in the medical literature to support this practice. Most clinical trials examining the use of topical corticosteroids after UVB exposure have shown minimal or no clinical improvement in the sunburn reaction.<sup><xref ref-type="bibr" rid="bibr6-1559827612460499">6</xref>,<xref ref-type="bibr" rid="bibr10-1559827612460499">10</xref></sup> In one controlled clinical trial, twice daily application of moderate potency topical corticosteroids starting 6 hours after UVB exposure and continued for up to 1 week did result in clinical improvement that was statistically significant on days 4 and 5.<sup><xref ref-type="bibr" rid="bibr12-1559827612460499">12</xref></sup> Given the weak data supporting the clinical effectiveness of topical corticosteroids and NSAIDs in patients with sunburn, symptomatic treatment with conservative therapies such as cool compresses and soothing emollients is frequently the most appropriate management option.</p>
</sec>
<sec id="section3-1559827612460499">
<title>Skin Pigmentation</title>
<p>Exposure to UVR can cause both transient pigment changes and longer lasting delayed tanning. Immediate pigment darkening, which occurs with exposure to UVA and some short wavelengths of visible light, has a grayish color and occurs immediately after UVA exposure, lasting 10 to 20 minutes.<sup><xref ref-type="bibr" rid="bibr3-1559827612460499">3</xref></sup> With higher doses of UVA, persistent pigment darkening occurs, which appears darker brown in color and lasts from 2 to 24 hours. Both immediate and persistent pigment darkening are due to oxidation of preexisting melanin and melanin precursors and metabolites.</p>
<p>Delayed tanning, which begins approximately 72 hours after UVR exposure, occurs with exposure to both UVA and UVB.<sup><xref ref-type="bibr" rid="bibr3-1559827612460499">3</xref></sup> With delayed tanning, the number and activity of melanocytes are increased. More specifically, there is increased melanocyte tyrosinase activity (rate-limiting enzyme in melanin synthesis), elongation and branching of melanocytes, increased size and number of melanocytes, and increased transfer of melanosomes from melanocytes to keratinocytes. It should be noted that UVB-induced tanning is always preceded by erythema, whereas perceptible erythema may not always occur before UVA-induced tanning. A common misconception is that obtaining a tan helps protect against sunburn.<sup><xref ref-type="bibr" rid="bibr13-1559827612460499">13</xref>,<xref ref-type="bibr" rid="bibr14-1559827612460499">14</xref></sup> However, tanning provides minimal photoprotection. On average, a UVB-induced tan affords a sun protection factor (SPF) of 3, and a visually identical UVA-induced tan results in an SPF of 1.4.<sup><xref ref-type="bibr" rid="bibr15-1559827612460499">15</xref></sup> Another frequent misconception is that tanning is safe as long as no sunburning occurs, but because UV-induced DNA damage is part of the molecular mechanism of tanning, “safe tanning” is an oxymoron.<sup><xref ref-type="bibr" rid="bibr14-1559827612460499">14</xref>,<xref ref-type="bibr" rid="bibr16-1559827612460499">16</xref></sup></p>
</sec>
<sec id="section4-1559827612460499">
<title>Ultraviolet Radiation and Skin Cancer Pathogenesis</title>
<p>In 1992, UVR from the sun was classified as a carcinogen by the International Agency for Research on Cancer.<sup><xref ref-type="bibr" rid="bibr17-1559827612460499">17</xref></sup> DNA is a chromophore for UVB radiation, and absorption of UVR by DNA results in DNA damage. Absorption of UVB by DNA results in the formation of 2 types of photoproducts. Cyclobutane pyrimidine dimers result from covalent binding of carbon atoms at the C5 and C6 positions of adjacent pyrimidines, and pyrimidine 6-4 pyrimidone photoproducts are formed by covalent binding between the C6 ad C4 positions of adjacent pyrimidines.<sup><xref ref-type="bibr" rid="bibr18-1559827612460499">18</xref></sup> Ideally, these photoproducts are repaired by cells, but when not repaired, C to T and CC to TT mutations occur. These mutations, which are known as the UV fingerprint mutations, are an initial step in the pathway to skin cancer.</p>
<p>The mechanisms underlying UVA-induced carcinogenesis are not as well understood. Unlike UVB, UVA is not well-absorbed by DNA,<sup><xref ref-type="bibr" rid="bibr19-1559827612460499">19</xref></sup> but skin exposure to UVA generates reactive oxygen species, which results in production of the guanine oxidation product 8-oxo-7 8-dihydroguanine in much larger amounts than oligonucleotide strand breaks and oxidized pyrimidine bases.<sup><xref ref-type="bibr" rid="bibr20-1559827612460499">20</xref></sup> 8-Oxo-7, 8-dihydroguanine is one of the major promutagenic DNA lesions resulting from oxidative damage from a variety of sources and can result in G to T and C to A mutations.<sup><xref ref-type="bibr" rid="bibr19-1559827612460499">19</xref>,<xref ref-type="bibr" rid="bibr21-1559827612460499">21</xref></sup> As with UVB, exposure to UVA also results in the formation of cyclobutane pyrimidine dimers, which likely also play an important role in UVA-induced carcinogenesis.<sup><xref ref-type="bibr" rid="bibr22-1559827612460499">22</xref></sup></p>
<p>Notably, UVR can cause mutations directly in the <italic>p53</italic> tumor suppressor gene. UV fingerprint <italic>p53</italic> mutations are very common in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) and are observed less frequently in melanoma.<sup><xref ref-type="bibr" rid="bibr17-1559827612460499">17</xref>,<xref ref-type="bibr" rid="bibr23-1559827612460499">23</xref></sup></p>
</sec>
<sec id="section5-1559827612460499">
<title>Immunosuppression</title>
<p>Ultraviolet radiation not only causes skin cancer by direct damage to DNA but also facilitates the growth of skin cancers by inducing a state of immunosuppression. Absorption of UVA and UVB by chromophores results in immune suppression via multiple pathways.<sup><xref ref-type="bibr" rid="bibr24-1559827612460499">24</xref>,<xref ref-type="bibr" rid="bibr25-1559827612460499">25</xref></sup> Langerhans cells, the primary antigen-presenting cells in the skin, show a decrease in number as well as function in response to UVR.<sup><xref ref-type="bibr" rid="bibr25-1559827612460499">25</xref></sup> When exposed to antigen, UV-irradiated Langerhans cells activate Th2 cells preferentially, resulting in activation of suppressor T cells and suppression of the immune response. Stimulation of the production of various cytokines, such as interleukin (IL)-1, IL-10, and TNF-α, and inhibition of cytokines, such as IL-12, also contributes to the immune suppression seen with UVR. In addition, UVR causes isomerization of urocanic acid to its cis isoform, which is an immune suppressant. Numerous other cells and molecules likely play a role in the multiple pathways of immune modulation induced by UVR.<sup><xref ref-type="bibr" rid="bibr24-1559827612460499">24</xref></sup></p>
</sec>
<sec id="section6-1559827612460499">
<title>Melanoma</title>
<p>Whereas the overall incidence of cancers tracked by the major cancer registries in the United States has decreased in the past several decades, numerous studies demonstrate a rapid increase in the incidence of melanoma over this time period.<sup><xref ref-type="bibr" rid="bibr26-1559827612460499">26</xref><xref ref-type="bibr" rid="bibr27-1559827612460499"/><xref ref-type="bibr" rid="bibr28-1559827612460499"/>-<xref ref-type="bibr" rid="bibr29-1559827612460499">29</xref></sup> Based on estimates from the Surveillance, Epidemiology, and End Results database, there was an increase of more than 600% in the incidence of melanoma between 1950 and 2000.<sup><xref ref-type="bibr" rid="bibr30-1559827612460499">30</xref></sup> The annual incidence of melanoma in the United States increased from 6.8 per 100 000 people in 1973 to 20.1 per 100 000 people in 2003 to 2007.<sup><xref ref-type="bibr" rid="bibr27-1559827612460499">27</xref></sup> Over the past 2 decades, young women have shown the most pronounced increase in melanoma incidence.<sup><xref ref-type="bibr" rid="bibr31-1559827612460499">31</xref></sup> The lifetime risk of melanoma has recently been estimated at 2.67% (1 in 37) for men and 1.79% (1 in 56) for women.<sup><xref ref-type="bibr" rid="bibr27-1559827612460499">27</xref></sup> Incidence of melanoma increases with age, but almost one third of cases are in patients below 50 years of age.<sup><xref ref-type="bibr" rid="bibr32-1559827612460499">32</xref></sup></p>
<p>Cutaneous melanoma classically presents as a pigmented lesion that exhibits features of the “ABCD” rule: asymmetry, border irregularity, color variegation, and diameter greater than 6 mm. Evolution of a pigmented lesion over time is also a feature that may be worrisome for melanoma. However, some melanomas, particularly nodular, desmoplastic, and amelanotic melanomas, may not show these classic features and can present a diagnostic challenge. Unlike nonmelanoma skin cancers, which very rarely metastasize, up to one fifth of melanoma patients develop metastatic melanoma, which is often eventually fatal.<sup><xref ref-type="bibr" rid="bibr33-1559827612460499">33</xref></sup> Based on the American Cancer Society estimates for the year 2010, approximately 68, 130 people in the United States were diagnosed with melanoma, and 8700 died of the disease.<sup><xref ref-type="bibr" rid="bibr29-1559827612460499">29</xref></sup></p>
<p>Ultraviolet radiation plays an important but complex role in the development of melanoma, and the nature of this role continues to be defined (<xref ref-type="table" rid="table2-1559827612460499">Table 2</xref>). The incidence of melanoma in a particular geographic location correlates positively with the average amount of UVR.<sup><xref ref-type="bibr" rid="bibr27-1559827612460499">27</xref></sup> Intermittent intense exposure to sunlight, rather than chronic exposure, appears to carry the highest risk for melanoma.<sup><xref ref-type="bibr" rid="bibr34-1559827612460499">34</xref></sup> Although some studies have focused on childhood sunburns as a risk factor for melanoma, more recent studies indicate that sunburns at any age increase melanoma risk. A 2008 meta-analysis demonstrated an association between the risk of melanoma and increased number of sunburns, irrespective of whether the sunburns occurred in childhood, adolescence, or adulthood.<sup><xref ref-type="bibr" rid="bibr35-1559827612460499">35</xref></sup> In a multicenter case–control study, more than 5 sunburns was associated with a 2-fold risk of melanoma, regardless of the age at which the sunburns occurred.<sup><xref ref-type="bibr" rid="bibr36-1559827612460499">36</xref></sup> Recent data indicate that exposure to tanning beds is also associated with an increased risk of melanoma.<sup><xref ref-type="bibr" rid="bibr37-1559827612460499">37</xref>,<xref ref-type="bibr" rid="bibr38-1559827612460499">38</xref></sup></p>
<table-wrap id="table2-1559827612460499" position="float">
<label>Table 2.</label>
<caption>
<p>Sun Exposure Patterns Associated With Melanoma, Squamous Cell Carcinoma, and Basal Cell Carcinoma.</p>
</caption>
<graphic alternate-form-of="table2-1559827612460499" xlink:href="10.1177_1559827612460499-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Melanoma</th>
<th align="center">Squamous Cell Carcinoma</th>
<th align="center">Basal Cell Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classic clinical presentation</td>
<td>Large asymmetric pigmented lesion with irregular borders and multiple colors</td>
<td>Erythematous plaque, may have scale or ulcer</td>
<td>Pearly papule with telangiectases, may have ulcer</td>
</tr>
<tr>
<td>Gender predisposed</td>
<td>Male</td>
<td>Male</td>
<td>Male</td>
</tr>
<tr>
<td>Most common location</td>
<td>Back (men) and lower extremities (women)</td>
<td>Head and neck</td>
<td>Head and neck</td>
</tr>
<tr>
<td>Associated pattern of sun exposure</td>
<td>Intermittent, intense exposure</td>
<td>Cumulative lifetime exposure</td>
<td>Intermittent, intense exposure likely more important than cumulative lifetime exposure</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The precise mechanism whereby a melanocyte is transformed into malignant melanoma remains to be elucidated, but UVR likely plays an important role by causing DNA damage in melanocytes and also possibly through immunosuppression. Certain gene mutations associated with melanoma, including <italic>CDKN2A</italic> and <italic>BRAF</italic>, are also important in melanoma pathogenesis. Activating mutations in <italic>BRAF</italic>, which encodes the serine/threonine protein kinase B-raf, cause constitutive activation of the MAP kinase pathway and are present in approximately 50% of melanomas.<sup><xref ref-type="bibr" rid="bibr39-1559827612460499">39</xref></sup> Vemurafenib, an inhibitor of the most common <italic>BRAF</italic> mutant (BRAF V600E [valine at position 600 replaced by glutamine], which accounts for 90% of <italic>BRAF</italic> mutations in melanoma), was recently approved by the US Food and Drug Administration (FDA) and several regulatory agencies in Europe for the treatment of metastatic melanoma in patients harboring this mutation. Mutations in <italic>CDKN2A</italic>, which encodes 2 tumor suppressor proteins, p16 and ARF (p14), are associated with familial melanoma.<sup><xref ref-type="bibr" rid="bibr27-1559827612460499">27</xref></sup> Interestingly, recent studies of melanomas have revealed UV fingerprint mutations in <italic>CDKN2A</italic> and other probable UVR-induced mutations in <italic>BRAF</italic>, providing evidence of a direct role for UVR in the mutagenesis of these important genes in melanomas.<sup><xref ref-type="bibr" rid="bibr17-1559827612460499">17</xref>,<xref ref-type="bibr" rid="bibr40-1559827612460499">40</xref>,<xref ref-type="bibr" rid="bibr41-1559827612460499">41</xref></sup></p>
</sec>
<sec id="section7-1559827612460499">
<title>Squamous Cell Carcinoma</title>
<p>Cutaneous squamous cell carcinoma is a tumor of keratinocytes and is the second most common skin cancer, accounting for approximately 20% of nonmelanoma skin cancers.<sup><xref ref-type="bibr" rid="bibr42-1559827612460499">42</xref></sup> The most common location for SCC is the head and neck, and 80% of cases occur in patients aged 60 or older. Males are affected more frequently than females. Patients typically present with firm, erythematous papules or plaques that may be smooth, scaly, or ulcerated and may cause bleeding, pain, and pruritus. The 5-year rate of metastasis for SCC is likely approximately 5%,<sup><xref ref-type="bibr" rid="bibr42-1559827612460499">42</xref>,<xref ref-type="bibr" rid="bibr43-1559827612460499">43</xref></sup> but estimates of metastatic risk vary widely in the literature, and some subtypes of SCC carry a much higher risk of metastasis than others.<sup><xref ref-type="bibr" rid="bibr44-1559827612460499">44</xref>,<xref ref-type="bibr" rid="bibr45-1559827612460499">45</xref></sup> Characteristics of SCC associated with a high risk for metastasis include location on the lip or ear and histopathologic features such as poor tumor differentiation or perineural invasion.<sup><xref ref-type="bibr" rid="bibr46-1559827612460499">46</xref></sup></p>
<p>Although SCCs may arise de novo, many develop from actinic keratoses, which are considered to be SCC precursors.<sup><xref ref-type="bibr" rid="bibr45-1559827612460499">45</xref></sup> Actinic keratoses present clinically as rough erythematous macules or papules that are often more easily identified by palpation than visual inspection. An individual actinic keratosis has only a small risk of progression to SCC, but treatment is warranted because it is not possible to determine which actinic keratoses will progress to invasive cancer. Furthermore, some actinic keratoses can be clinically indistinguishable from SCC, and biopsy may be required when a presumed actinic keratosis is not responding to standard treatment. Risk factors for SCC include exposure to UVR, fair skin, various genodermatoses, ionizing radiation, human papillomavirus infection, chronically inflamed skin (such as chronic ulcers), and immunosuppression (especially in the context of organ transplantation).<sup><xref ref-type="bibr" rid="bibr42-1559827612460499">42</xref></sup> Interestingly, in contrast to the general population, organ transplant patients have more SCCs than basal cell carcinomas.</p>
<p>Exposure to UVR has been well-established as the most common and important cause of SCC. Whereas intermittent intense UVR exposure is associated with an increased risk of melanoma, cumulative lifetime UVR exposure is believed to be the primary determinant of SCC risk.<sup><xref ref-type="bibr" rid="bibr47-1559827612460499">47</xref></sup> SCCs favor areas on the head and neck that have maximal sun exposure.<sup><xref ref-type="bibr" rid="bibr48-1559827612460499">48</xref></sup> In addition, studies have demonstrated that SCC risk is higher in patients living closer to the equator, in patients with occupational light exposure, and in patients with higher estimated total cumulative solar exposure.<sup><xref ref-type="bibr" rid="bibr49-1559827612460499">49</xref>,<xref ref-type="bibr" rid="bibr50-1559827612460499">50</xref></sup></p>
</sec>
<sec id="section8-1559827612460499">
<title>Basal Cell Carcinoma</title>
<p>Basal cell carcinoma is the most common skin cancer, accounting for approximately 80% of nonmelanoma skin cancers.<sup><xref ref-type="bibr" rid="bibr42-1559827612460499">42</xref></sup> BCC is also the most common malignant tumor in white populations.<sup><xref ref-type="bibr" rid="bibr51-1559827612460499">51</xref></sup> Although BCCs may cause significant disfigurement via local tissue destruction, metastatic disease is very rare. The most common BCC subtype, nodular BCC, classically presents as a pearly papule with telangiectases, sometimes associated with a central nonhealing erosion or ulceration. Like SCCs, BCCs are most common on the head and neck of elderly patients, are more common in men than women, and more common in patients with fair skin. UVR, immunosuppression, and various genodermatoses are also risk factors.<sup><xref ref-type="bibr" rid="bibr52-1559827612460499">52</xref></sup></p>
<p>As with SCC and melanoma, UVR exposure is a well-established risk factor for BCC. However, the pattern of sun exposure responsible for BCC development appears to be more complex than the exposure pattern associated with SCC.<sup><xref ref-type="bibr" rid="bibr51-1559827612460499">51</xref></sup> Although BCC was classically believed to be associated with cumulative sun exposure like SCC, more recent studies indicate that intense intermittent UVR is the main risk factor for BCC (<xref ref-type="table" rid="table2-1559827612460499">Table 2</xref>). As with SCC, the risk of BCC correlates with proximity to the equator, and BCCs occur most frequently in areas that receive the highest average amount of sun, such as the head and neck. However, BCCs are also associated with number of sunburns and recreational (intermittent) sun exposure during childhood and adolescence.<sup><xref ref-type="bibr" rid="bibr51-1559827612460499">51</xref>,<xref ref-type="bibr" rid="bibr53-1559827612460499">53</xref><xref ref-type="bibr" rid="bibr54-1559827612460499"/><xref ref-type="bibr" rid="bibr55-1559827612460499"/>-<xref ref-type="bibr" rid="bibr56-1559827612460499">56</xref></sup></p>
</sec>
<sec id="section9-1559827612460499">
<title>Photoaging</title>
<p>Chronic exposure to UVR accounts for many of the age-associated changes seen in the skin. These changes are termed photoaging and include freckles, lentigines, leather-like coarseness, rhytides, inelasticity, purpura, and yellow-gray discoloration.<sup><xref ref-type="bibr" rid="bibr33-1559827612460499">33</xref>,<xref ref-type="bibr" rid="bibr57-1559827612460499">57</xref></sup> Photoaged skin demonstrates changes in dermal connective tissue, with damaged and disorganized collagen fibrils and accumulation of elastic material.<sup><xref ref-type="bibr" rid="bibr58-1559827612460499">58</xref></sup> This elastic material appears on slides stained with hematoxylin and eosin as basophilic blue-gray material in the upper dermis and is termed solar elastosis.</p>
<p>The dermal connective tissue damage observed in photoaging is mediated by matrix metalloproteinases, enzymes responsible for degradation of collagen and other extracellular matrix proteins in dermal connective tissue.<sup><xref ref-type="bibr" rid="bibr58-1559827612460499">58</xref></sup> Via multiple molecular mechanisms, UVR causes increased activity of the transcription factor activator protein-1, which controls transcription of matrix metalloproteinases.<sup><xref ref-type="bibr" rid="bibr59-1559827612460499">59</xref></sup> Both UVB and UVA are involved in the pathogenesis of photoaging, but UVA is believed to play a larger role because, relative to UVB, UVA has a greater average depth of penetration in the dermis and a greater abundance in natural sunlight.<sup><xref ref-type="bibr" rid="bibr57-1559827612460499">57</xref></sup></p>
</sec>
<sec id="section10-1559827612460499">
<title>Vitamin D</title>
<p>Vitamin D, which has long been known to be essential for skeletal health, has been in the news over the past few years because of reported associations of vitamin D deficiency with a wide variety of medical problems beyond osteoporosis, including malignancy, autoimmune disease, infection, type 2 diabetes, cardiovascular disease, cognitive decline, and even all-cause mortality.<sup><xref ref-type="bibr" rid="bibr60-1559827612460499">60</xref></sup> Physicians who recommend sun protection are often asked about whether this can adversely affect vitamin D levels. The term “Vitamin D” refers to the 2 fat-soluble prohormones, vitamin D2 (ergocalciferol, made by plants and fungi) and vitamin D3 (cholecalciferol, made by animals and humans). Both forms are used in supplements for humans. The biologically active form of vitamin D is 1,25-dihydroxyvitamin D (1,25-OH-vitamin D), which regulates the transcription of vitamin D–responsive genes.<sup><xref ref-type="bibr" rid="bibr61-1559827612460499">61</xref></sup> However, the most commonly used test to assess vitamin D levels in patients is serum 25-hydroxyvitamin D (25-OH-vitamin D).</p>
<p>Endogenous synthesis of vitamin D<sub>3</sub> in humans takes place in the basal and suprabasal layers of the epidermis, where 7-dehydrocholesterol (pro-vitamin D<sub>3</sub>) is converted into pre-vitamin D<sub>3</sub> by UVB radiation.<sup><xref ref-type="bibr" rid="bibr62-1559827612460499">62</xref>,<xref ref-type="bibr" rid="bibr63-1559827612460499">63</xref></sup> Nonenzymatic isomerization of pre-vitamin D<sub>3</sub> produces cholecalciferol (vitamin D<sub>3</sub>), which enters the bloodstream and is carried to the liver by vitamin D binding protein.<sup><xref ref-type="bibr" rid="bibr62-1559827612460499">62</xref></sup> In the liver, vitamin D<sub>3</sub> is hydroxylated by 25-hydroxylase, producing 25-OH-vitamin D (calcidiol). In the final step of vitamin D synthesis, 25-OH-vitamin D is carried by vitamin D binding protein to the kidney where 25-OH-vitamin D is hydroxylated by 1-alpha-hydroxylase, forming the active form of vitamin D, 1,25-OH-vitamin D (calcitriol). Evidence from in vitro studies demonstrates that this final step can also take place in certain nonrenal tissues that express 1-alpha-hydroxylase, such as epidermal keratinocytes.<sup><xref ref-type="bibr" rid="bibr63-1559827612460499">63</xref></sup></p>
<p>Another source of vitamin D<sub>3</sub> is exogenous intake, including dietary intake and oral supplements. Ingested vitamin D<sub>3</sub> is converted to active vitamin D via the pathway detailed above, but the first 2 steps are bypassed (see <xref ref-type="fig" rid="fig1-1559827612460499">Figure 1</xref>), and UVB thus does not play a role in the process. Natural dietary sources of vitamin D<sub>3</sub> are limited; fatty fish, including salmon, tuna, and mackerel, and cod liver oil are some of the best sources.<sup><xref ref-type="bibr" rid="bibr62-1559827612460499">62</xref>,<xref ref-type="bibr" rid="bibr64-1559827612460499">64</xref></sup> However, in the United States a wide variety of popular food items are fortified with vitamin D, including almost the entire United States milk supply and some brands of breakfast cereals, orange juice, yogurt, and margarine.<sup><xref ref-type="bibr" rid="bibr62-1559827612460499">62</xref>,<xref ref-type="bibr" rid="bibr64-1559827612460499">64</xref></sup> Numerous supplements containing vitamin D<sub>3</sub> and vitamin D<sub>2</sub> are available, but only vitamin D<sub>2</sub> is available as a high-dose prescription supplement.<sup><xref ref-type="bibr" rid="bibr65-1559827612460499">65</xref></sup> It is controversial whether vitamin D<sub>3</sub> supplements are more effective at increasing serum 25-OH-vitamin D levels than vitamin D<sub>2</sub> supplements. Some studies have shown equivalence of vitamin D<sub>2</sub> and D<sub>3</sub>,<sup><xref ref-type="bibr" rid="bibr66-1559827612460499">66</xref>,<xref ref-type="bibr" rid="bibr67-1559827612460499">67</xref></sup> whereas others have demonstrated increased effectiveness of vitamin D<sub>3</sub>.<sup><xref ref-type="bibr" rid="bibr68-1559827612460499">68</xref>,<xref ref-type="bibr" rid="bibr69-1559827612460499">69</xref></sup> Because some data indicate superior efficacy of vitamin D<sub>3</sub>, some experts recommended vitamin D<sub>3</sub> over vitamin D<sub>2</sub>, especially when dosing is infrequent (less than once weekly), as vitamin D<sub>3</sub> has a longer half-life.<sup><xref ref-type="bibr" rid="bibr70-1559827612460499">70</xref></sup></p>
<fig id="fig1-1559827612460499" position="float">
<label>Figure 1.</label>
<caption>
<p>Synthesis of vitamin D.</p>
</caption>
<graphic xlink:href="10.1177_1559827612460499-fig1.tif"/>
</fig>
<p>Institute of Medicine (IOM) committee released a public health report in 2010 detailing the recommended daily allowance (RDA) for vitamin D. The IOM recommendations for nutritional requirements are based on strong scientific evidence for the role of vitamin D in skeletal health, as they concluded that the evidence linking vitamin D to extraskeletal outcomes is inconsistent and not strong enough to influence their recommendations.<sup><xref ref-type="bibr" rid="bibr71-1559827612460499">71</xref></sup> The RDA for vitamin D is 600 IU/day for healthy people aged 1 to 70 years and 800 IU/day for those aged 71 years and older. These RDAs correspond to a serum 25-OH-vitmain D level of at least 20 mg/mL, which meets the requirements for at least 97.5% of the population. For infants, there is no official RDA, but adequate intake is estimated at 400 IU/day. Per the IOM recommendations, the tolerable upper intake levels are 4000 IU/day for individuals aged 9 and older. All recommendations were based on the assumption of minimal or no sunlight exposure.</p>
<p>Given that endogenous vitamin D synthesis requires UVB irradiation, sunscreen theoretically could block this process, and concern has been raised that widespread recommendations for sunscreen use might lead to vitamin D deficiency. However, a review of the literature revealed that although under very strictly controlled conditions sunscreens can result in significant reduction in the production of vitamin D, normal use of sunscreens does not typically lead to vitamin D insufficiency.<sup><xref ref-type="bibr" rid="bibr72-1559827612460499">72</xref></sup> The lack of vitamin D deficiency resulting from normal use of sunscreen may be explained by the fact that individuals commonly apply sunscreens at much lower densities than the concentration of 2 mg/cm<sup>2</sup> that is mandated for SPF testing and also may not reapply sunscreens as often as recommended.<sup><xref ref-type="bibr" rid="bibr72-1559827612460499">72</xref><xref ref-type="bibr" rid="bibr73-1559827612460499"/>-<xref ref-type="bibr" rid="bibr74-1559827612460499">74</xref></sup> Furthermore, sunscreen is not usually applied to all exposed skin.<sup><xref ref-type="bibr" rid="bibr72-1559827612460499">72</xref>,<xref ref-type="bibr" rid="bibr75-1559827612460499">75</xref></sup></p>
<p>Because of the risk of skin cancer associated with UVR, intentional sun exposure should not be recommended as a means for increasing vitamin D levels. For those who cannot meet the age-appropriate RDA for vitamin D through dietary consumption, oral vitamin D supplements are usually a much safer and more reliable alternative than sun exposure. The median dietary intake of vitamin D in the United States ranges from approximately 272 to 396 IU/day; therefore, most healthy individuals require dietary changes or a supplement to reach the RDA; for instance, a 75-year-old person with a dietary intake of 300 IU/day of vitamin D requires 500 IU/day supplementation to reach the RDA of 800 IU/day.<sup><xref ref-type="bibr" rid="bibr76-1559827612460499">76</xref></sup> Patients can be reassured that that sun protection does not affect these recommendations, as the IOM RDA guidelines were made with the assumption of minimal to no UVR exposure.</p>
</sec>
<sec id="section11-1559827612460499">
<title>Sunscreen</title>
<p>In the United States, sunscreens are considered over-the-counter medications and are regulated by the FDA. The purpose of sunscreens is to protect against the harmful effects of UVB and UVA irradiation. Ideally, sunscreens should be applied to all sun-exposed skin areas 30 minutes before sun exposure and, when outdoors, reapplied every 2 hours. Sunscreen should ideally be applied at a density of 2 mg/cm<sup>2</sup>, which is approximately 1 ounce (2 tablespoons) for an average-sized adult. There are 17 sunscreen active ingredients currently approved in the FDA monograph, each of which has different advantages and disadvantages. Many sunscreen products contain multiple active sunscreen ingredients.</p>
<p>Of the 17 US FDA-approved sunscreen ingredients, only 2 are inorganic (physical) filters, and the rest are organic (chemical) filters (see <xref ref-type="table" rid="table3-1559827612460499">Table 3</xref>).<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> The inorganic filters, titanium dioxide and zinc oxide, function by absorbing, scattering, and reflecting UVR. Benefits of these agents include their photostability, low allergenicity, and broad protection against UVA and UVB.<sup><xref ref-type="bibr" rid="bibr78-1559827612460499">78</xref></sup> Titanium dioxide imparts better UVB protection and has a whiter color, whereas zinc oxide offers better UVA coverage.<sup><xref ref-type="bibr" rid="bibr79-1559827612460499">79</xref></sup> The main detraction from inorganic filters is that they may appear opaque, which is cosmetically undesirable.</p>
<table-wrap id="table3-1559827612460499" position="float">
<label>Table 3.</label>
<caption>
<p>United States FDA-Approved Sunscreen Filters.</p>
</caption>
<graphic alternate-form-of="table3-1559827612460499" xlink:href="10.1177_1559827612460499-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Filter Name</th>
<th/>
<th/>
</tr>
<tr>
<th align="left">USAN (INCI Name, Brand Name)</th>
<th align="center">Type of Filter</th>
<th align="center">UV Action Spectrum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminobenzoates (PABA derivatives)</td>
<td>Organic</td>
<td>UVB</td>
</tr>
<tr>
<td> PABA (para-aminobenzoic acid)</td>
<td/>
<td/>
</tr>
<tr>
<td> Padimate-O (octyl dimethyl PABA)</td>
<td/>
<td/>
</tr>
<tr>
<td>Cinnamates</td>
<td>Organic</td>
<td>UVB</td>
</tr>
<tr>
<td> Cinoxate (2-ethoxyethyl p-methoxycinnamate)</td>
<td/>
<td/>
</tr>
<tr>
<td> Octinoxate (octyl methoxycinnamate [OMC])</td>
<td/>
<td/>
</tr>
<tr>
<td>Salicylates</td>
<td>Organic</td>
<td>UVB</td>
</tr>
<tr>
<td> Octisalate (octyl salicylate)</td>
<td/>
<td/>
</tr>
<tr>
<td> Homosalate (homomenthyl salicylate)</td>
<td/>
<td/>
</tr>
<tr>
<td> Trolamine salicylate (triethanolamine salicylate)</td>
<td/>
<td/>
</tr>
<tr>
<td>Ensulizole (phenylbenzimidazole sulfonic acid)</td>
<td>Organic</td>
<td>UVB</td>
</tr>
<tr>
<td>Anthralates</td>
<td>Organic</td>
<td>UVA2</td>
</tr>
<tr>
<td> Meradimate (menthyl anthranilate)</td>
<td/>
<td/>
</tr>
<tr>
<td>Benzophenones</td>
<td>Organic</td>
<td>UVB, UVA2</td>
</tr>
<tr>
<td> Oxybenzone (benzophenone-3)</td>
<td/>
<td/>
</tr>
<tr>
<td> Sulisobenzone (benzophenone-4)</td>
<td/>
<td/>
</tr>
<tr>
<td> Dioxybenzone (benzophenone-8)</td>
<td/>
<td/>
</tr>
<tr>
<td>Camphors</td>
<td>Organic</td>
<td>UVB, UVA</td>
</tr>
<tr>
<td> Ecamsule<sup><xref ref-type="table-fn" rid="table-fn3-1559827612460499">a</xref></sup> (terephthalylidene dicamphor sulfonic acid, Mexoryl SX)</td>
<td/>
<td/>
</tr>
<tr>
<td>Dibenzoylmethanes</td>
<td>Organic</td>
<td>UVA1</td>
</tr>
<tr>
<td> Avobenzone (butyl methoxydibenzoylmethane, Parsol 1789)</td>
<td/>
<td/>
</tr>
<tr>
<td>Octocrylene</td>
<td>Organic</td>
<td>UVB, UVA2</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>Inorganic</td>
<td>UVB, UVA<sup><xref ref-type="table-fn" rid="table-fn4-1559827612460499">b</xref></sup></td>
</tr>
<tr>
<td>Zinc oxide</td>
<td>Inorganic</td>
<td>UVB, UVA<sup><xref ref-type="table-fn" rid="table-fn4-1559827612460499">b</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1559827612460499">
<p>Abbreviations: USAN, United States Adopted Name; INCI, International Nomenclature of Cosmetic Ingredients.</p>
</fn>
<fn id="table-fn3-1559827612460499">
<label>a</label>
<p>Approved under the new drug application as a component of certain sunscreen formulations.</p>
</fn>
<fn id="table-fn4-1559827612460499">
<label>b</label>
<p>Absorption varies with particle size.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>To improve cosmetic acceptability, many sunscreen products are now manufactured with smaller particles of titanium dioxide and zinc oxide, which results in a more transparent product that blends more readily into the skin.<sup><xref ref-type="bibr" rid="bibr80-1559827612460499">80</xref></sup> Some of these products contain nanoparticles (&lt;100 nm) of titanium dioxide or zinc oxide, and concerns have been raised about the safety of these products.<sup><xref ref-type="bibr" rid="bibr81-1559827612460499">81</xref>,<xref ref-type="bibr" rid="bibr82-1559827612460499">82</xref></sup> These concerns stem from the theoretical possibility that the small size of nanoparticles might enable penetration into the deeper layers of the skin where they could potentially cause toxicity. A few isolated cell experiments have suggested that nanoparticles of zinc oxide and titanium dioxide may cause DNA damage via induction of reactive oxygen species in the presence of UVR.<sup><xref ref-type="bibr" rid="bibr82-1559827612460499">82</xref></sup> However, in vitro and in vivo studies of nanosized titanium dioxide and zinc oxide have demonstrated that when titanium dioxide and zinc oxide nanoparticles are applied to intact skin, they do not penetrate deeper than the inviable stratum corneum, where there is no potential for cytotoxicity.<sup><xref ref-type="bibr" rid="bibr81-1559827612460499">81</xref></sup> Therefore, current evidence indicates that sunscreens containing nanoparticles are safe for use on intact skin. Furthermore, nanoparticles of titanium dioxide and zinc oxide can be coated with manganese or other materials to reduce the potential of generating oxygen radicals on exposure to UVR.<sup><xref ref-type="bibr" rid="bibr83-1559827612460499">83</xref>,<xref ref-type="bibr" rid="bibr84-1559827612460499">84</xref></sup> Nonetheless, as the incorporation of nanoparticles into sunscreens becomes more prevalent, further data are needed to assess whether nanoparticle application to damaged skin results in deeper skin penetration and potential toxicity.</p>
<p>Organic filters, which work by absorbing UVR, can be divided into UVB filters and UVA filters based on their action spectra. In the United States, octinoxate is the most commonly used UVB filter.<sup><xref ref-type="bibr" rid="bibr1-1559827612460499">1</xref></sup> Although there are many FDA-approved UVB filters, there are only a handful of organic filters with effective UVA coverage, and most of these UVA filters cover predominately UVA2. Avobenzone is the most effective UVA filter available in the United States and is the only agent with significant coverage in the UVA1 range.<sup><xref ref-type="bibr" rid="bibr85-1559827612460499">85</xref></sup> However, because of its inherent photolability, avobenzone must be combined with photostabilizing compounds such as octocrylene.<sup><xref ref-type="bibr" rid="bibr86-1559827612460499">86</xref></sup> See <xref ref-type="table" rid="table3-1559827612460499">Table 3</xref> for a complete listing of FDA-approved sunscreen filters and their action spectra.<sup><xref ref-type="bibr" rid="bibr87-1559827612460499">87</xref></sup></p>
<p>One popular UVA filter, oxybenzone, is the most common cause of photoallergic reactions to UV filters. However, considering the widespread use of sunscreens, the true incidence of UV filter–induced photoallergic reactions is low. Concerns have also been expressed about the safety of oxybenzone. These concerns stem from the fact that oxybenzone is absorbed systemically in humans at a rate of 1% to 2% after topical application and that it has been reported to have estrogenic and anti-androgenic activity in in vitro studies and in an animal model.<sup><xref ref-type="bibr" rid="bibr82-1559827612460499">82</xref>,<xref ref-type="bibr" rid="bibr88-1559827612460499">88</xref>,<xref ref-type="bibr" rid="bibr89-1559827612460499">89</xref></sup> However, human studies of oxybenzone have demonstrated no detectable hormonal disruption with topical use of oxybenzone.<sup><xref ref-type="bibr" rid="bibr87-1559827612460499">87</xref></sup> Furthermore, to place the animal model in perspective, it was estimated that the average US woman would have to apply oxybenzone daily to 25% of her body surface area for an unrealistic duration of 277.0 years (or 100% of her body surface area for 69.3 years) in order to obtain the concentrations observed in the animal study.<sup><xref ref-type="bibr" rid="bibr87-1559827612460499">87</xref></sup> The available scientific evidence shows a lack of systemic effects in humans with topical use of oxybenzones, and the FDA currently stands behind the safety of oxybenzone and all other approved UV filters.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> However, the FDA will continue to monitor oxybenzone for potential systemic effects as new data become available.</p>
<p>The safety of an ingredient present in some sunscreens, retinyl palmitate, has also recently been questioned in the media. Retinoyl palmitate, which is a storage form of retinol (vitamin A) in human skin, is not a UVR filter but is commonly found in sunscreens and other topical products. Although some concerns have been raised that retinoyl palmitate may be carcinogenic, in vitro and animal studies do not show evidence of carcinogenicity, and decades of clinical use of topical products with retinyl palmitate in humans support its safety.<sup><xref ref-type="bibr" rid="bibr82-1559827612460499">82</xref></sup></p>
<p>Sun protection factor is the widely accepted standard for quantifying the UVB protection of sunscreens. SPF is defined as the ratio of the lowest dose of UVR required to produce erythema on sunscreen-protected skin after application of 2 mg/cm<sup>2</sup> of product, compared with the lowest UVR dose needed to produce the same erythema on skin without sunscreen. Patients often ask what SPF is recommended for sun protection. The recommendation by the American Academy of Dermatology is the generous application of sunscreen with a minimum SPF of 30.<sup><xref ref-type="bibr" rid="bibr90-1559827612460499">90</xref></sup> Whether SPF values higher than 30 offer a benefit compared with SPF-30 sunscreens is controversial. Under laboratory conditions, the additional absorption of UVR by SPF-30+ sunscreens is minimal; for instance, SPF-15 sunscreens absorb 93.3% of the UVR, whereas SPF-30 sunscreens absorb 96.7%, and SPF-60 sunscreens absorb 98.3%.<sup><xref ref-type="bibr" rid="bibr91-1559827612460499">91</xref></sup> Some have argued that because consumers do not apply adequate amounts of sunscreen, the effective SPF is much lower than the labeled SPF, and high SPF values therefore have substantial clinical benefit.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> In 2011, the FDA proposed a maximum label of SPF-50+ after concluding that there are insufficient data to support the contention that SPF values above 50 produce additional clinical benefit. In response, a recent study was published demonstrating SPF-70 and SPF-100 sunscreens do offer clinical benefit in comparison with SPF-30 and SPF-50 sunscreens when the sunscreens are applied at the inadequate density of 0.5 mg/cm<sup>2</sup>.<sup><xref ref-type="bibr" rid="bibr73-1559827612460499">73</xref>,<xref ref-type="bibr" rid="bibr90-1559827612460499">90</xref></sup> Given that individuals usually apply sunscreen at densities of 0.5 to 1 mg/cm<sup>2</sup> rather than at the recommended 2 mg/cm<sup>2</sup>,<sup><xref ref-type="bibr" rid="bibr73-1559827612460499">73</xref>,<xref ref-type="bibr" rid="bibr90-1559827612460499">90</xref></sup> this study likely has real-world applicability.</p>
<p>In summary, if sunscreen is applied at the recommended density of 2 mg/cm<sup>2</sup>, there appears to be minimal additional benefit to using sunscreens above SPF-30. However, recent data indicate that SPF-70 and SPF-100 sunscreens may offer superior protection relative to SPF-30 and SPF-50 sunscreens when sunscreen is applied at the inadequate density used by the average person.<sup><xref ref-type="bibr" rid="bibr90-1559827612460499">90</xref></sup> The final FDA recommendations remain to be determined, but there is concern that allowing SPF labels higher than 50 may engender a false sense of security in sunscreen users, encouraging them to spend more time in the sun and ultimately resulting in more UVR-related skin damage.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup></p>
<p>UVA protection in sunscreen is also critical. Sunscreens labeled broad spectrum have both UVA and UVB coverage. In the United States for many years, sunscreens with any UVA filters could be labeled broad spectrum, and there was no way for consumers to know whether the UVA coverage of a given product was adequate. In June 2011, the FDA released a final rule on sunscreen labeling and effectiveness testing (the “final rule”) that addresses this issue. Any sunscreen that is labeled as broad spectrum must have a critical wavelength of greater than or equal to 370 nm, which indicates that it has adequate UVA coverage.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> The critical wavelength is the wavelength below which 90% of the total area under the absorbance curve resides. It is important to understand that as UVB absorption (which correlates with SPF) increases, UVA absorption must increase proportionately to maintain a critical wavelength of 370 nm. Therefore, a sunscreen with a higher SPF must meet a higher minimum standard for UVA absorption before it can be labeled as broad spectrum. This allows consumers to more easily compare sunscreen products in terms that are already familiar to the general public; consumers simply can select a product based on the SPF, provided the sunscreen is broad spectrum. The FDA requires that all broad spectrum sunscreen products distributed after the final rule goes into effect (June 2012) display the words “Broad Spectrum” and “SPF” in the same font size and color and on the same line or adjacent to each other to emphasize the importance of broad spectrum coverage.</p>
<p>The FDA final rule has several other provisions. Products that claim to be water-resistant must be labeled as “water resistant (40 minutes)” or “water resistant (80 minutes)” based on standardized water resistance testing.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> The misleading claims “water proof,” “sweat proof,” and “sun block” are no longer allowed. Another change is that broad spectrum sunscreens with SPF-15 or greater can display the following claim in the “Drug Facts” box on the back of the product package: “If used as directed with other sun protection measures, (sunscreens) decrease the risk of skin cancer and early skin aging caused by the sun.” The final rule also calls for more specific instructions about how to appropriately apply sunscreens.</p>
<p>There are several outstanding issues that are still being debated. The FDA has proposed capping the maximum SPF at 50+ but is currently still seeking additional comments about this proposal.<sup><xref ref-type="bibr" rid="bibr77-1559827612460499">77</xref></sup> Another issue that is being considered is which sunscreen dosage forms can be marketed as sunscreens. The FDA has proposed that oils, lotions, creams, gels, butters, pastes, and ointments be considered satisfactory sunscreen dosing forms whereas wipes, towelettes, powders, body washes, and shampoos should not be marketed as sunscreens. Whether spray forms of sunscreens should be eligible for marketing as sunscreens is still being debated.</p>
<p>Sunscreen labels recommend that parents ask a physician about the use of sunscreen on infants below 6 months of age. In comparison with adults, infants have a higher body surface area-to-mass ratio, and there may also be differences in absorption, metabolism, and excretion of sunscreen products in young infants relative to adults.<sup><xref ref-type="bibr" rid="bibr92-1559827612460499">92</xref></sup> In addition, sunscreens are not tested on young infants. For these reasons, sun avoidance and protective clothing are recommended as the preferred method of sun protection in infants below 6 months of age. However, both the American Academy of Dermatology and the American Academy of Pediatrics recommend the use of sunscreen for infants in this age range on small exposed areas of the body as an alternative method of photoprotection when full protection cannot be provided by protective clothing and sun avoidance. When selecting a sunscreen for infants and toddlers, inorganic filters are typically preferred as these have a lower potential for skin and eye irritation.</p>
</sec>
<sec id="section12-1559827612460499">
<title>Other Methods of Sun Protection</title>
<p>When counseling patients about sun protection, physicians frequently recommend sunscreen use but often fail to discuss other methods of sun protection.<sup><xref ref-type="bibr" rid="bibr93-1559827612460499">93</xref></sup> Sun avoidance is the most effective method of sun protection, although complete avoidance is obviously not practical. Minimizing sun exposure between 10 <sc>am</sc> and 2 <sc>pm</sc>, the time period of peak UVR exposure, and staying in the shade when possible during these hours are important behavior modifications.<sup><xref ref-type="bibr" rid="bibr1-1559827612460499">1</xref></sup> Wearing a wide-brimmed hat, sunglasses, and sun-protective clothing should also be encouraged.</p>
<p>Clothing that causes scattering of UVR can provide effective protection against the sun, but the protection against UVB is greater than that against UVA. The UV protection provided by clothing is quantified by the UV protection factor (UPF), which is analogous to the SPF of sunscreen. UPF is determined as follows: (<italic>a</italic>) transmission of UVR through fabric is measured with a spectrophotometer and (<italic>b</italic>) UPF is calculated using a formula that combines the UV transmission data with 2 weighting factor values, solar spectral irradiance and erythema effectiveness, at each UV wavelength.<sup><xref ref-type="bibr" rid="bibr94-1559827612460499">94</xref></sup> Because UVB is primarily responsible for the erythema response, similar to SPF, UPF is more heavily affected by the UVB component than the UVA component of the UVR spectrum.</p>
<p>UPF is influenced by multiple variables, which are summarized in <xref ref-type="table" rid="table4-1559827612460499">Table 4</xref>.<sup><xref ref-type="bibr" rid="bibr95-1559827612460499">95</xref></sup> In general, thicker, heavier fabrics and more tightly woven fabrics have a higher UPF. With respect to specific materials, polyester typically provides the highest UPF, followed by wool, nylon, and silk. Cotton, viscose, rayon, and linen have a lower UPF. Unbleached fabrics have a higher UPF than bleached textiles, and darkly colored fabrics have a higher UPF than lighter fabrics. For cotton clothing, washing causes an increase in UPF because of shrinkage of the porosity of the fabric. Reduced UPF occurs with stretching of fabrics, wear and tear on fabrics, and when there is a small distance between skin and fabric. Water has a variable effect on UPF; wetness decreases the UPF of cotton but increases the UPF of linen, viscose, and polyester. To increase the UPF of clothing, fabrics can be chemically treated with UV absorbers and optical whiteners during the manufacturing process.<sup><xref ref-type="bibr" rid="bibr96-1559827612460499">96</xref></sup> Commercially available laundry products containing UV absorbers Rit<sup>®</sup> SunGuard<sup>TM</sup>, which contains TinosorbTM FD are also very effective in increasing UPF.<sup><xref ref-type="bibr" rid="bibr94-1559827612460499">94</xref>,<xref ref-type="bibr" rid="bibr96-1559827612460499">96</xref>,<xref ref-type="bibr" rid="bibr97-1559827612460499">97</xref></sup> As the wide variety of factors involved in determination of UPF can be difficult to remember, one simple strategy is to advise patients to wear polyester clothing as opposed to cotton when spending time in the sun. For patients who prefer cotton, cotton clothing marketed as sun-protective (owing to pretreatment with UV absorbers) and use of laundry products containing UV absorbers are practical alternatives. Wide-brimmed hats (&gt;7.5 cm), which provide better sun protection for the head and neck than hats with smaller brims, should also be recommended.<sup><xref ref-type="bibr" rid="bibr1-1559827612460499">1</xref></sup></p>
<table-wrap id="table4-1559827612460499" position="float">
<label>Table 4.</label>
<caption>
<p>Variables Affecting UV Protection Factor of Clothing.</p>
</caption>
<graphic alternate-form-of="table4-1559827612460499" xlink:href="10.1177_1559827612460499-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Clothing Property</th>
<th align="center">Associated UPF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thicker, heavier fabrics</td>
<td>Higher</td>
</tr>
<tr>
<td>Darkly colored fabric</td>
<td>Higher</td>
</tr>
<tr>
<td>Washed fabric</td>
<td>Higher (cotton)</td>
</tr>
<tr>
<td>Made from polyester, wool, nylon, or silk</td>
<td>Higher</td>
</tr>
<tr>
<td>Made from cotton, viscose, rayon, or linen</td>
<td>Lower</td>
</tr>
<tr>
<td>Bleached fabric</td>
<td>Lower</td>
</tr>
<tr>
<td>Stretched fabric</td>
<td>Lower</td>
</tr>
<tr>
<td>Wear and tear on fabric</td>
<td>Lower</td>
</tr>
<tr>
<td>Small distance between skin and fabric</td>
<td>Lower</td>
</tr>
<tr>
<td>Wet fabric</td>
<td>Lower (cotton); higher (linen, viscose, polyester)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Another important component of sun protection, which may be neglected by dermatologists who focus on the skin, is eye protection. The cornea and lens absorb UVR in people of all ages, whereas the retina absorbs UVR predominantly in children because lens opacities that develop with age protect the retina in adults.<sup><xref ref-type="bibr" rid="bibr98-1559827612460499">98</xref></sup> Chronic UVR exposure is a risk factor for many ocular diseases, including cortical cataracts, pterygium, SCC of the cornea and conjunctiva, conjunctival melanoma, and possibly uveal melanoma. Acute UVR exposure can also cause multiple ocular problems, including photokeratitis and photoconjunctivitis.</p>
<p>Sunglasses can be effective at protecting the eyes from UVR, although some lenses transmit much more UVR than others. There is a standard guideline in the United States that categorizes the different types of sunglasses according to the degree of shading and the UV absorption profile, but this standard is voluntary, so it can sometimes be difficult to find a pair of sunglasses with adequate protection.<sup><xref ref-type="bibr" rid="bibr99-1559827612460499">99</xref></sup> Ideally, consumers should seek glasses that block as much UV radiation as possible while allowing the transmission of visible light.</p>
<p>UVR exposure of the eye has several important differences from exposure of the skin. Because the eye is shielded by the eyelids and brow ridges and because looking at direct light causes squinting, reflection (off grass, sand, ground, water, or snow) and scattering (for instance, from patchy cloud cover) are the most important sources of UV exposure. It is therefore critical that the eyes be protected from all directions, but most sunglasses are designed for fashion and comfort, so the lateral and inferior borders of the eyes are typically poorly shielded.<sup><xref ref-type="bibr" rid="bibr99-1559827612460499">99</xref></sup> Tight-fitting sunglasses with a wrap-around design provide better protection than small, flat lenses worn away from the eye. UV-blocking contact lenses are also effective at protecting the eyes from UVR.<sup><xref ref-type="bibr" rid="bibr100-1559827612460499">100</xref></sup> In addition, unlike sunglasses, which often prevent the protective squint mechanism by blocking visible light, UVR-blocking contact lenses do not decrease the squint mechanism. However, unlike sunglasses, contact lenses cannot provide protection for the periocular skin.</p>
<p>In contrast to the relationship between peak sunlight hours and the skin, off-peak hours of sunlight are more dangerous to the eyes than peak hours.<sup><xref ref-type="bibr" rid="bibr99-1559827612460499">99</xref></sup> During the morning and late afternoon, the UV incident angle is low, allowing the UVR to bypass the defense of the brow ridge and eyelid. Furthermore, the light intensity is weaker during off-peak hours, so protective squinting does not occur. Because sun protection campaigns typically focus on skin protection and advise sun protection mostly between 10 <sc>am</sc> and 2 <sc>pm</sc>, people may neglect to wear sunglasses during the important off-peak morning and late afternoon hours. Patients should be counseled on the importance of protective eyewear use during off-peak hours.</p>
</sec>
<sec id="section13-1559827612460499">
<title>Indoor Tanning</title>
<p>In the United States, indoor tanning is used by almost 30 million people annually, including 2.3 million adolescents.<sup><xref ref-type="bibr" rid="bibr101-1559827612460499">101</xref></sup> Indoor tanning rates are highest among young females, aged 17 to 30 years.<sup><xref ref-type="bibr" rid="bibr102-1559827612460499">102</xref></sup> The incidence of both melanoma and nonmelanoma skin cancer in the United States is rapidly increasing, especially in young women.<sup><xref ref-type="bibr" rid="bibr103-1559827612460499">103</xref>,<xref ref-type="bibr" rid="bibr104-1559827612460499">104</xref></sup> A recent systematic review specifically linked indoor tanning use with an increased risk of both melanoma and SCC.<sup><xref ref-type="bibr" rid="bibr105-1559827612460499">105</xref></sup> An even higher relative risk of melanoma was found in those who started using tanning beds before 35 years of age. Although the systematic review did not find an elevated risk of BCC in tanning bed users, a large case–control study did demonstrate an increased risk of both BCC and SCC with use of indoor tanning.<sup><xref ref-type="bibr" rid="bibr106-1559827612460499">106</xref></sup></p>
<p>In recent years, the dangers of tanning beds have been recognized publicly around the world. The World Health Organization classified tanning beds as a human carcinogen in 2009, and multiple countries have imposed restrictions or bans on the indoor tanning industry, generally targeting minors.<sup><xref ref-type="bibr" rid="bibr107-1559827612460499">107</xref></sup> In the United States, California and Vermont are the only states with a complete ban on indoor tanning for minors, but 31 states have enacted restrictions, and efforts to increase restrictions are ongoing.<sup><xref ref-type="bibr" rid="bibr108-1559827612460499">108</xref></sup></p>
<p>To facilitate tanning, indoor tanning devices emit UVR at much higher doses than are found in sunlight.<sup><xref ref-type="bibr" rid="bibr107-1559827612460499">107</xref></sup> In addition, to minimize erythema, indoor tanning devices also use an increased UVA to UVB ratio relative to natural sunlight. One study quantifying UVR output at 62 indoor tanning locations found much higher mean UVA (192.1 W/m<sup>2</sup>) and UVB (0.35 W/m<sup>2</sup>) doses than the UVR in noon sunlight in Washington, DC in the summer.<sup><xref ref-type="bibr" rid="bibr109-1559827612460499">109</xref></sup> Relative to the noon DC summer sunlight, the mean UVA dose was approximately 4 times as high and the UVB dose was twice as high in the indoor tanning salons. Furthermore, 95% of tanners exceeded the FDA-recommended exposure limits.</p>
<p>Some proponents of indoor tanning argue that tanning beds can have health benefits by increasing vitamin D levels.<sup><xref ref-type="bibr" rid="bibr107-1559827612460499">107</xref></sup> However, tanning beds emit predominantly UVA, which makes them inefficient at increasing endogenous vitamin D synthesis, as this is a UVB-dependent process. Furthermore, for those at risk for vitamin D deficiency, vitamin D supplements are a much safer and more reliable source of vitamin D than indoor tanning or exposure to natural sunlight.</p>
<p>There is substantial evidence indicating that individuals may become addicted to indoor tanning. UVA exposure can cause an elevation of plasma endogenous opioids,<sup><xref ref-type="bibr" rid="bibr110-1559827612460499">110</xref></sup> and symptoms of opiate withdrawal occurred when frequent tanners were given the opiate antagonist naltrexone in a randomized controlled trial.<sup><xref ref-type="bibr" rid="bibr111-1559827612460499">111</xref></sup> A recent study using a modified version of the <italic>Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision)</italic> (<italic>DSM-IV-TR</italic>) criteria for substance-related disorders in college students who had used indoor tanning facilities found that 39.3% of tanners met <italic>DSM-IV-TR</italic> criteria for tanning addiction.<sup><xref ref-type="bibr" rid="bibr112-1559827612460499">112</xref></sup> In summary, indoor tanning can be an addictive behavior, and it is a well-documented carcinogen with no legitimate health benefits. The dermatology community strongly supports public education campaigns about this issue as well as the ongoing efforts to ban minors from engaging in this dangerous activity.<sup><xref ref-type="bibr" rid="bibr107-1559827612460499">107</xref></sup></p>
</sec>
<sec id="section14-1559827612460499">
<title>Conclusion</title>
<p>UVR clearly has a broad impact on the skin and has the potential to lead to a myriad problems, including melanoma and nonmelanoma skin cancer, sunburns, immunosuppression, and ocular problems. Other adverse effects of UV exposure include photodermatoses (including polymorphous light eruption, actinic prurigo, chronic actinic dermatitis, solar urticaria, and hydroa vacciniforme), phototoxicity and photoallergy (caused by drugs or chemicals), and photoaging (wrinkling, uneven pigmentation, telangiectases, and other undesirable skin changes).<sup><xref ref-type="bibr" rid="bibr107-1559827612460499">107</xref></sup> Educating patients about the dangers of UVR and the most effective forms of sun protection is an important task that will most effectively be accomplished through the joint efforts of primary care physicians, dermatologists, and other health care practitioners.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1559827612460499">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kullavanijaya</surname><given-names>P</given-names></name>
<name><surname>Lim</surname><given-names>HW</given-names></name>
</person-group>. <article-title>Photoprotection</article-title>. <source>J Am Acad Dermatol</source>. <year>2005</year>;<volume>52</volume>:<fpage>937</fpage>-<lpage>958</lpage>.</citation>
</ref>
<ref id="bibr2-1559827612460499">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>AR</given-names></name>
<name><surname>Chadwick</surname><given-names>CA</given-names></name>
<name><surname>Harrison</surname><given-names>GI</given-names></name>
<name><surname>Nikaido</surname><given-names>O</given-names></name>
<name><surname>Ramsden</surname><given-names>J</given-names></name>
<name><surname>Potten</surname><given-names>CS</given-names></name>
</person-group>. <article-title>The similarity of action spectra for thymine dimers in human epidermis and erythema suggests that DNA is the chromophore for erythema</article-title>. <source>J Invest Dermatol</source>. <year>1998</year>;<volume>111</volume>:<fpage>982</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr3-1559827612460499">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Honigsmann</surname><given-names>H</given-names></name>
</person-group>. <article-title>Erythema and pigmentation</article-title>. <source>Photodermatol Photoimmunol Photomed</source>. <year>2002</year>;<volume>18</volume>(<issue>2</issue>):<fpage>75</fpage>-<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr4-1559827612460499">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marrot</surname><given-names>L</given-names></name>
<name><surname>Meunier</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Skin DNA photodamage and its biological consequences</article-title>. <source>J Am Acad Dermatol</source>. <year>2008</year>;<volume>58</volume>(<issue>5</issue> <supplement>suppl 2</supplement>):<fpage>S139</fpage>-<lpage>S148</lpage>.</citation>
</ref>
<ref id="bibr5-1559827612460499">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roberts</surname><given-names>WE</given-names></name>
</person-group>. <article-title>Skin type classification systems old and new</article-title>. <source>Dermatol Clin</source>. <year>2009</year>;<volume>27</volume>:<fpage>529</fpage>-<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr6-1559827612460499">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Faurschou</surname><given-names>A</given-names></name>
<name><surname>Wulf</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Topical corticosteroids in the treatment of acute sunburn: a randomized, double-blind clinical trial</article-title>. <source>Arch Dermatol</source>. <year>2008</year>;<volume>144</volume>:<fpage>620</fpage>-<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr7-1559827612460499">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Antoniou</surname><given-names>C</given-names></name>
<name><surname>Kosmadaki</surname><given-names>MG</given-names></name>
<name><surname>Stratigos</surname><given-names>AJ</given-names></name>
<name><surname>Katsambas</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Sunscreens: what’s important to know</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2008</year>;<volume>22</volume>:<fpage>1110</fpage>-<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr8-1559827612460499">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsumura</surname><given-names>Y</given-names></name>
<name><surname>Ananthaswamy</surname><given-names>HN</given-names></name>
</person-group>. <article-title>Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine</article-title>. <source>Expert Rev Mol Med</source>. <year>2002</year>;<volume>4</volume>(<issue>26</issue>):<fpage>1</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr9-1559827612460499">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhodes</surname><given-names>LE</given-names></name>
<name><surname>Belgi</surname><given-names>G</given-names></name>
<name><surname>Parslew</surname><given-names>R</given-names></name>
<name><surname>McLoughlin</surname><given-names>L</given-names></name>
<name><surname>Clough</surname><given-names>GF</given-names></name>
<name><surname>Friedmann</surname><given-names>PS</given-names></name>
</person-group>. <article-title>Ultraviolet-B-induced erythema is mediated by nitric oxide and prostaglandin E2 in combination</article-title>. <source>J Invest Dermatol</source>. <year>2001</year>;<volume>117</volume>:<fpage>880</fpage>-<lpage>885</lpage>.</citation>
</ref>
<ref id="bibr10-1559827612460499">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Driscoll</surname><given-names>MS</given-names></name>
<name><surname>Wagner</surname><given-names>RF</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>Clinical management of the acute sunburn reaction</article-title>. <source>Cutis</source>. <year>2000</year>;<volume>66</volume>:<fpage>53</fpage>-<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr11-1559827612460499">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magnette</surname><given-names>J</given-names></name>
<name><surname>Kienzler</surname><given-names>JL</given-names></name>
<name><surname>Alekxandrova</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>The efficacy and safety of low-dose diclofenac sodium 0.1% gel for the symptomatic relief of pain and erythema associated with superficial natural sunburn</article-title>. <source>Eur J Dermatol</source>. <year>2004</year>;<volume>14</volume>:<fpage>238</fpage>-<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr12-1559827612460499">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duteil</surname><given-names>L</given-names></name>
<name><surname>Queille-Roussel</surname><given-names>C</given-names></name>
<name><surname>Lorenz</surname><given-names>B</given-names></name>
<name><surname>Thieroff-Ekerdt</surname><given-names>R</given-names></name>
<name><surname>Ortonne</surname><given-names>JP</given-names></name>
</person-group>. <article-title>A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers</article-title>. <source>Clin Exp Dermatol</source>. <year>2002</year>;<volume>27</volume>:<fpage>314</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr13-1559827612460499">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliver</surname><given-names>H</given-names></name>
<name><surname>Ferguson</surname><given-names>J</given-names></name>
<name><surname>Moseley</surname><given-names>H</given-names></name>
</person-group>. <article-title>Quantitative risk assessment of sunbeds: impact of new high power lamps</article-title>. <source>Br J Dermatol</source>. <year>2007</year>;<volume>157</volume>:<fpage>350</fpage>-<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr14-1559827612460499">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woo</surname><given-names>DK</given-names></name>
<name><surname>Eide</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Tanning beds, skin cancer, and vitamin D: an examination of the scientific evidence and public health implications</article-title>. <source>Dermatol Ther</source>. <year>2010</year>;<volume>23</volume>:<fpage>61</fpage>-<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr15-1559827612460499">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gange</surname><given-names>RW</given-names></name>
<name><surname>Blackett</surname><given-names>AD</given-names></name>
<name><surname>Matzinger</surname><given-names>EA</given-names></name>
<name><surname>Sutherland</surname><given-names>BM</given-names></name>
<name><surname>Kochevar</surname><given-names>IE</given-names></name>
</person-group>. <article-title>Comparative protection efficiency of UVA- and UVB-induced tans against erythema and formation of endonuclease-sensitive sites in DNA by UVB in human skin</article-title>. <source>J Invest Dermatol</source>. <year>1985</year>;<volume>85</volume>:<fpage>362</fpage>-<lpage>364</lpage>.</citation>
</ref>
<ref id="bibr16-1559827612460499">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eller</surname><given-names>MS</given-names></name>
<name><surname>Ostrom</surname><given-names>K</given-names></name>
<name><surname>Gilchrest</surname><given-names>BA</given-names></name>
</person-group>. <article-title>DNA damage enhances melanogenesis</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>;<volume>93</volume>:<fpage>1087</fpage>-<lpage>1092</lpage>.</citation>
</ref>
<ref id="bibr17-1559827612460499">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garibyan</surname><given-names>L</given-names></name>
<name><surname>Fisher</surname><given-names>DE</given-names></name>
</person-group>. <article-title>How sunlight causes melanoma</article-title>. <source>Curr Oncol Rep</source>. <year>2010</year>;<volume>12</volume>:<fpage>319</fpage>-<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr18-1559827612460499">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ravanat</surname><given-names>JL</given-names></name>
<name><surname>Douki</surname><given-names>T</given-names></name>
<name><surname>Cadet</surname><given-names>J</given-names></name>
</person-group>. <article-title>Direct and indirect effects of UV radiation on DNA and its components</article-title>. <source>J Photochem Photobiol B</source>. <year>2001</year>;<volume>63</volume>:<fpage>88</fpage>-<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr19-1559827612460499">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mouret</surname><given-names>S</given-names></name>
<name><surname>Baudouin</surname><given-names>C</given-names></name>
<name><surname>Charveron</surname><given-names>M</given-names></name>
<name><surname>Favier</surname><given-names>A</given-names></name>
<name><surname>Cadet</surname><given-names>J</given-names></name>
<name><surname>Douki</surname><given-names>T</given-names></name>
</person-group>. <article-title>Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>:<fpage>13765</fpage>-<lpage>13770</lpage>.</citation>
</ref>
<ref id="bibr20-1559827612460499">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cadet</surname><given-names>J</given-names></name>
<name><surname>Douki</surname><given-names>T</given-names></name>
</person-group>. <article-title>Oxidatively generated damage to DNA by UVA radiation in cells and human skin</article-title>. <source>J Invest Dermatol</source>. <year>2011</year>;<volume>131</volume>:<fpage>1005</fpage>-<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr21-1559827612460499">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beard</surname><given-names>WA</given-names></name>
<name><surname>Batra</surname><given-names>VK</given-names></name>
<name><surname>Wilson</surname><given-names>SH</given-names></name>
</person-group>. <article-title>DNA polymerase structure-based insight on the mutagenic properties of 8-oxoguanine</article-title>. <source>Mutat Res</source>. <year>2010</year>;<volume>703</volume>:<fpage>18</fpage>-<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr22-1559827612460499">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mouret</surname><given-names>S</given-names></name>
<name><surname>Leccia</surname><given-names>MT</given-names></name>
<name><surname>Bourrain</surname><given-names>JL</given-names></name>
<name><surname>Douki</surname><given-names>T</given-names></name>
<name><surname>Beani</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Individual photosensitivity of human skin and UVA-induced pyrimidine dimers in DNA</article-title>. <source>J Invest Dermatol</source>. <year>2011</year>;<volume>131</volume>:<fpage>1539</fpage>-<lpage>1546</lpage>.</citation>
</ref>
<ref id="bibr23-1559827612460499">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benjamin</surname><given-names>CL</given-names></name>
<name><surname>Ullrich</surname><given-names>SE</given-names></name>
<name><surname>Kripke</surname><given-names>ML</given-names></name>
<name><surname>Ananthaswamy</surname><given-names>HN</given-names></name>
</person-group>. <article-title>p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer</article-title>. <source>Photochem Photobiol</source>. <year>2008</year>;<volume>84</volume>:<fpage>55</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr24-1559827612460499">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norval</surname><given-names>M</given-names></name>
<name><surname>Halliday</surname><given-names>GM</given-names></name>
</person-group>. <article-title>The consequences of UV-induced immunosuppression for human health</article-title>. <source>Photochem Photobiol</source>. <year>2011</year>;<volume>87</volume>:<fpage>965</fpage>-<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr25-1559827612460499">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanneman</surname><given-names>KK</given-names></name>
<name><surname>Cooper</surname><given-names>KD</given-names></name>
<name><surname>Baron</surname><given-names>ED</given-names></name>
</person-group>. <article-title>Ultraviolet immunosuppression: mechanisms and consequences</article-title>. <source>Dermatol Clin</source>. <year>2006</year>;<volume>24</volume>:<fpage>19</fpage>-<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr26-1559827612460499">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Linos</surname><given-names>E</given-names></name>
<name><surname>Swetter</surname><given-names>SM</given-names></name>
<name><surname>Cockburn</surname><given-names>MG</given-names></name>
<name><surname>Colditz</surname><given-names>GA</given-names></name>
<name><surname>Clarke</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Increasing burden of melanoma in the United States</article-title>. <source>J Invest Dermatol</source>. <year>2009</year>;<volume>129</volume>:<fpage>1666</fpage>-<lpage>1674</lpage>.</citation>
</ref>
<ref id="bibr27-1559827612460499">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuong</surname><given-names>W</given-names></name>
<name><surname>Cheng</surname><given-names>LS</given-names></name>
<name><surname>Armstrong</surname><given-names>AW</given-names></name>
</person-group>. <article-title>Melanoma: epidemiology, diagnosis, treatment, and outcomes</article-title>. <source>Dermatol Clin</source>. <year>2012</year>;<volume>30</volume>:<fpage>113</fpage>-<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr28-1559827612460499">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howe</surname><given-names>HL</given-names></name>
<name><surname>Wingo</surname><given-names>PA</given-names></name>
<name><surname>Thun</surname><given-names>MJ</given-names></name><etal/>
</person-group>. <article-title>Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends</article-title>. <source>J Natl Cancer Inst</source>. <year>2001</year>;<volume>93</volume>:<fpage>824</fpage>-<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr29-1559827612460499">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jemal</surname><given-names>A</given-names></name>
<name><surname>Siegel</surname><given-names>R</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Ward</surname><given-names>E</given-names></name>
</person-group>. <article-title>Cancer statistics, 2010</article-title>. <source>CA Cancer J Clin</source>. <year>2010</year>;<volume>60</volume>:<fpage>277</fpage>-<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr30-1559827612460499">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Homsi</surname><given-names>J</given-names></name>
<name><surname>Kashani-Sabet</surname><given-names>M</given-names></name>
<name><surname>Messina</surname><given-names>JL</given-names></name>
<name><surname>Daud</surname><given-names>A</given-names></name>
</person-group>. <article-title>Cutaneous melanoma: prognostic factors</article-title>. <source>Cancer Control</source>. <year>2005</year>;<volume>12</volume>:<fpage>223</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr31-1559827612460499">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Purdue</surname><given-names>MP</given-names></name>
<name><surname>Freeman</surname><given-names>LE</given-names></name>
<name><surname>Anderson</surname><given-names>WF</given-names></name>
<name><surname>Tucker</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Recent trends in incidence of cutaneous melanoma among US Caucasian young adults</article-title>. <source>J Invest Dermatol</source>. <year>2008</year>;<volume>128</volume>:<fpage>2905</fpage>-<lpage>2908</lpage>.</citation>
</ref>
<ref id="bibr32-1559827612460499">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jennings</surname><given-names>L</given-names></name>
<name><surname>Murphy</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Predicting outcome in melanoma: where are we now?</article-title> <source>Br J Dermatol</source>. <year>2009</year>;<volume>161</volume>:<fpage>496</fpage>-<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr33-1559827612460499">
<label>33.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Bolognia</surname><given-names>JL</given-names></name>
<name><surname>Jorizzo</surname><given-names>JL</given-names></name>
<name><surname>Schaffer</surname><given-names>JV</given-names></name>
</person-group>, eds. <source>Dermatology</source>. <edition>3rd ed.</edition> <publisher-name>Elsevier</publisher-name>; <year>2012</year>.</citation>
</ref>
<ref id="bibr34-1559827612460499">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gandini</surname><given-names>S</given-names></name>
<name><surname>Sera</surname><given-names>F</given-names></name>
<name><surname>Cattaruzza</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Meta-analysis of risk factors for cutaneous melanoma: II</article-title>. <article-title>Sun exposure</article-title>. <source>Eur J Cancer</source>. <year>2005</year>;<volume>41</volume>:<fpage>45</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr35-1559827612460499">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dennis</surname><given-names>LK</given-names></name>
<name><surname>Vanbeek</surname><given-names>MJ</given-names></name>
<name><surname>Beane Freeman</surname><given-names>LE</given-names></name>
<name><surname>Smith</surname><given-names>BJ</given-names></name>
<name><surname>Dawson</surname><given-names>DV</given-names></name>
<name><surname>Coughlin</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis</article-title>. <source>Ann Epidemiol</source>. <year>2008</year>;<volume>18</volume>:<fpage>614</fpage>-<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr36-1559827612460499">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfahlberg</surname><given-names>A</given-names></name>
<name><surname>Kolmel</surname><given-names>KF</given-names></name>
<name><surname>Gefeller</surname><given-names>O</given-names></name>
</person-group>. <article-title>Timing of excessive ultraviolet radiation and melanoma: epidemiology does not support the existence of a critical period of high susceptibility to solar ultraviolet radiation-induced melanoma</article-title>. <source>Br J Dermatol</source>. <year>2001</year>;<volume>144</volume>:<fpage>471</fpage>-<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr37-1559827612460499">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lazovich</surname><given-names>D</given-names></name>
<name><surname>Vogel</surname><given-names>RI</given-names></name>
<name><surname>Berwick</surname><given-names>M</given-names></name>
<name><surname>Weinstock</surname><given-names>MA</given-names></name>
<name><surname>Anderson</surname><given-names>KE</given-names></name>
<name><surname>Warshaw</surname><given-names>EM</given-names></name>
</person-group>. <article-title>Indoor tanning and risk of melanoma: a case-control study in a highly exposed population</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2010</year>;<volume>19</volume>:<fpage>1557</fpage>-<lpage>1568</lpage>.</citation>
</ref>
<ref id="bibr38-1559827612460499">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fears</surname><given-names>TR</given-names></name>
<name><surname>Sagebiel</surname><given-names>RW</given-names></name>
<name><surname>Halpern</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Sunbeds and sunlamps: who used them and their risk for melanoma</article-title>. <source>Pigment Cell Melanoma Res</source>. <year>2011</year>;<volume>24</volume>:<fpage>574</fpage>-<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr39-1559827612460499">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finn</surname><given-names>L</given-names></name>
<name><surname>Markovic</surname><given-names>SN</given-names></name>
<name><surname>Joseph</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Therapy for metastatic melanoma: the past, present, and future</article-title>. <source>BMC Med</source>. <year>2012</year>;<volume>10</volume>:<fpage>23</fpage>.</citation>
</ref>
<ref id="bibr40-1559827612460499">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peris</surname><given-names>K</given-names></name>
<name><surname>Chimenti</surname><given-names>S</given-names></name>
<name><surname>Fargnoli</surname><given-names>MC</given-names></name>
<name><surname>Valeri</surname><given-names>P</given-names></name>
<name><surname>Kerl</surname><given-names>H</given-names></name>
<name><surname>Wolf</surname><given-names>P</given-names></name>
</person-group>. <article-title>UV fingerprint CDKN2a but no p14ARF mutations in sporadic melanomas</article-title>. <source>J Invest Dermatol</source>. <year>1999</year>;<volume>112</volume>:<fpage>825</fpage>-<lpage>826</lpage>.</citation>
</ref>
<ref id="bibr41-1559827612460499">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Besaratinia</surname><given-names>A</given-names></name>
<name><surname>Pfeifer</surname><given-names>GP</given-names></name>
</person-group>. <article-title>Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma</article-title>. <source>Hum Mutat</source>. <year>2008</year>;<volume>29</volume>:<fpage>983</fpage>-<lpage>991</lpage>.</citation>
</ref>
<ref id="bibr42-1559827612460499">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alam</surname><given-names>M</given-names></name>
<name><surname>Ratner</surname><given-names>D</given-names></name>
</person-group>. <article-title>Cutaneous squamous-cell carcinoma</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>:<fpage>975</fpage>-<lpage>983</lpage>.</citation>
</ref>
<ref id="bibr43-1559827612460499">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brantsch</surname><given-names>KD</given-names></name>
<name><surname>Meisner</surname><given-names>C</given-names></name>
<name><surname>Schonfisch</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study</article-title>. <source>Lancet Oncol</source>. <year>2008</year>;<volume>9</volume>:<fpage>713</fpage>-<lpage>720</lpage>.</citation>
</ref>
<ref id="bibr44-1559827612460499">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullen</surname><given-names>JT</given-names></name>
<name><surname>Feng</surname><given-names>L</given-names></name>
<name><surname>Xing</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Invasive squamous cell carcinoma of the skin: defining a high-risk group</article-title>. <source>Ann Surg Oncol</source>. <year>2006</year>;<volume>13</volume>:<fpage>902</fpage>-<lpage>909</lpage>.</citation>
</ref>
<ref id="bibr45-1559827612460499">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassarino</surname><given-names>DS</given-names></name>
<name><surname>Derienzo</surname><given-names>DP</given-names></name>
<name><surname>Barr</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one</article-title>. <source>J Cutan Pathol</source>. <year>2006</year>;<volume>33</volume>:<fpage>191</fpage>-<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr46-1559827612460499">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brougham</surname><given-names>ND</given-names></name>
<name><surname>Dennett</surname><given-names>ER</given-names></name>
<name><surname>Cameron</surname><given-names>R</given-names></name>
<name><surname>Tan</surname><given-names>ST</given-names></name>
</person-group>. <article-title>The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors</article-title> [published online May 16, 2012]. <source>J Surg Oncol</source>. doi:<pub-id pub-id-type="doi">10.1002/jso.23155.</pub-id></citation>
</ref>
<ref id="bibr47-1559827612460499">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>J</given-names></name>
<name><surname>Seidler</surname><given-names>A</given-names></name>
<name><surname>Diepgen</surname><given-names>TL</given-names></name>
<name><surname>Bauer</surname><given-names>A</given-names></name>
</person-group>. <article-title>Occupational ultraviolet light exposure increases the risk for the development of cutaneous squamous cell carcinoma: a systematic review and meta-analysis</article-title>. <source>Br J Dermatol</source>. <year>2011</year>;<volume>164</volume>:<fpage>291</fpage>-<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr48-1559827612460499">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leman</surname><given-names>JA</given-names></name>
<name><surname>McHenry</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Basal cell carcinoma: still an enigma</article-title>. <source>Arch Dermatol</source>. <year>2001</year>;<volume>137</volume>:<fpage>1239</fpage>-<lpage>1240</lpage>.</citation>
</ref>
<ref id="bibr49-1559827612460499">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramos</surname><given-names>J</given-names></name>
<name><surname>Villa</surname><given-names>J</given-names></name>
<name><surname>Ruiz</surname><given-names>A</given-names></name>
<name><surname>Armstrong</surname><given-names>R</given-names></name>
<name><surname>Matta</surname><given-names>J</given-names></name>
</person-group>. <article-title>UV dose determines key characteristics of nonmelanoma skin cancer</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2004</year>;<volume>13</volume>:<fpage>2006</fpage>-<lpage>2011</lpage>.</citation>
</ref>
<ref id="bibr50-1559827612460499">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>BK</given-names></name>
<name><surname>Kricker</surname><given-names>A</given-names></name>
</person-group>. <article-title>The epidemiology of UV induced skin cancer</article-title>. <source>J Photochem Photobiol B</source>. <year>2001</year>;<volume>63</volume>:<fpage>8</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr51-1559827612460499">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dessinioti</surname><given-names>C</given-names></name>
<name><surname>Antoniou</surname><given-names>C</given-names></name>
<name><surname>Katsambas</surname><given-names>A</given-names></name>
<name><surname>Stratigos</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Basal cell carcinoma: what’s new under the sun</article-title>. <source>Photochem Photobiol</source>. <year>2010</year>;<volume>86</volume>:<fpage>481</fpage>-<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr52-1559827612460499">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kwasniak</surname><given-names>LA</given-names></name>
<name><surname>Garcia-Zuazaga</surname><given-names>J</given-names></name>
</person-group>. <article-title>Basal cell carcinoma: evidence-based medicine and review of treatment modalities</article-title>. <source>Int J Dermatol</source>. <year>2011</year>;<volume>50</volume>:<fpage>645</fpage>-<lpage>658</lpage>.</citation>
</ref>
<ref id="bibr53-1559827612460499">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kricker</surname><given-names>A</given-names></name>
<name><surname>Armstrong</surname><given-names>BK</given-names></name>
<name><surname>English</surname><given-names>DR</given-names></name>
<name><surname>Heenan</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia</article-title>. <source>Int J Cancer</source>. <year>1995</year>;<volume>60</volume>:<fpage>489</fpage>-<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr54-1559827612460499">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Corona</surname><given-names>R</given-names></name>
<name><surname>Dogliotti</surname><given-names>E</given-names></name>
<name><surname>D’Errico</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Risk factors for basal cell carcinoma in a Mediterranean population: role of recreational sun exposure early in life</article-title>. <source>Arch Dermatol</source>. <year>2001</year>;<volume>137</volume>:<fpage>1162</fpage>-<lpage>1168</lpage>.</citation>
</ref>
<ref id="bibr55-1559827612460499">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walther</surname><given-names>U</given-names></name>
<name><surname>Kron</surname><given-names>M</given-names></name>
<name><surname>Sander</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor</article-title>. <source>Br J Dermatol</source>. <year>2004</year>;<volume>151</volume>:<fpage>170</fpage>-<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr56-1559827612460499">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pelucchi</surname><given-names>C</given-names></name>
<name><surname>Di Landro</surname><given-names>A</given-names></name>
<name><surname>Naldi</surname><given-names>L</given-names></name>
<name><surname>La Vecchia</surname><given-names>C</given-names></name>
</person-group>. <article-title>Risk factors for histological types and anatomic sites of cutaneous basal-cell carcinoma: an Italian case-control study</article-title>. <source>J Invest Dermatol</source>. <year>2007</year>;<volume>127</volume>:<fpage>935</fpage>-<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr57-1559827612460499">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaar</surname><given-names>M</given-names></name>
<name><surname>Gilchrest</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Photoageing: mechanism, prevention and therapy</article-title>. <source>Br J Dermatol</source>. <year>2007</year>;<volume>157</volume>:<fpage>874</fpage>-<lpage>887</lpage>.</citation>
</ref>
<ref id="bibr58-1559827612460499">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quan</surname><given-names>T</given-names></name>
<name><surname>Qin</surname><given-names>Z</given-names></name>
<name><surname>Xia</surname><given-names>W</given-names></name>
<name><surname>Shao</surname><given-names>Y</given-names></name>
<name><surname>Voorhees</surname><given-names>JJ</given-names></name>
<name><surname>Fisher</surname><given-names>GJ</given-names></name>
</person-group>. <article-title>Matrix-degrading metalloproteinases in photoaging</article-title>. <source>J Investig Dermatol Symp Proc</source>. <year>2009</year>;<volume>14</volume>(<issue>1</issue>):<fpage>20</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr59-1559827612460499">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rabe</surname><given-names>JH</given-names></name>
<name><surname>Mamelak</surname><given-names>AJ</given-names></name>
<name><surname>McElgunn</surname><given-names>PJ</given-names></name>
<name><surname>Morison</surname><given-names>WL</given-names></name>
<name><surname>Sauder</surname><given-names>DN</given-names></name>
</person-group>. <article-title>Photoaging: mechanisms and repair</article-title>. <source>J Am Acad Dermatol</source>. <year>2006</year>;<volume>55</volume>:<fpage>1</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr60-1559827612460499">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Engelman</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Vitamin D recommendations: the saga continues</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>3065</fpage>-<lpage>3066</lpage>.</citation>
</ref>
<ref id="bibr61-1559827612460499">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geller</surname><given-names>JL</given-names></name>
<name><surname>Adams</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Vitamin D therapy</article-title>. <source>Curr Osteoporos Rep</source>. <year>2008</year>;<volume>6</volume>:<fpage>5</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr62-1559827612460499">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanchinathan</surname><given-names>V</given-names></name>
<name><surname>Lim</surname><given-names>HW</given-names></name>
</person-group>. <article-title>A dermatologist’s perspective on vitamin D</article-title>. <source>Mayo Clin Proc</source>. <year>2012</year>;<volume>87</volume>(<issue>4</issue>):<fpage>372</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr63-1559827612460499">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lehmann</surname><given-names>B</given-names></name>
<name><surname>Meurer</surname><given-names>M</given-names></name>
</person-group>. <article-title>Vitamin D metabolism</article-title>. <source>Dermatol Ther</source>. <year>2010</year>;<volume>23</volume>:<fpage>2</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr64-1559827612460499">
<label>64.</label>
<citation citation-type="gov">
<collab>Office of Dietary Supplements</collab>. <article-title>Dietary supplement fact sheet: vitamin D</article-title>. <ext-link ext-link-type="uri" xlink:href="http://dietary-supplements.info.nih.gov/factsheets/vitamind.asp#h3">http://dietary-supplements.info.nih.gov/factsheets/vitamind.asp#h3</ext-link>. <access-date>Accessed April 12, 2012</access-date>.</citation>
</ref>
<ref id="bibr65-1559827612460499">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binkley</surname><given-names>N</given-names></name>
<name><surname>Krueger</surname><given-names>D</given-names></name>
</person-group>. <article-title>Evaluation and correction of low vitamin D status</article-title>. <source>Curr Osteoporos Rep</source>. <year>2008</year>;<volume>6</volume>(<issue>3</issue>):<fpage>95</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr66-1559827612460499">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holick</surname><given-names>MF</given-names></name>
<name><surname>Biancuzzo</surname><given-names>RM</given-names></name>
<name><surname>Chen</surname><given-names>TC</given-names></name><etal/>
</person-group>. <article-title>Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2008</year>;<volume>93</volume>:<fpage>677</fpage>-<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr67-1559827612460499">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thacher</surname><given-names>TD</given-names></name>
<name><surname>Obadofin</surname><given-names>MO</given-names></name>
<name><surname>O’Brien</surname><given-names>KO</given-names></name>
<name><surname>Abrams</surname><given-names>SA</given-names></name>
</person-group>. <article-title>The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>:<fpage>3314</fpage>-<lpage>3321</lpage>.</citation>
</ref>
<ref id="bibr68-1559827612460499">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Houghton</surname><given-names>LA</given-names></name>
<name><surname>Vieth</surname><given-names>R</given-names></name>
</person-group>. <article-title>The case against ergocalciferol (vitamin D2) as a vitamin supplement</article-title>. <source>Am J Clin Nutr</source>. <year>2006</year>;<volume>84</volume>:<fpage>694</fpage>-<lpage>697</lpage>.</citation>
</ref>
<ref id="bibr69-1559827612460499">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binkley</surname><given-names>N</given-names></name>
<name><surname>Gemar</surname><given-names>D</given-names></name>
<name><surname>Engelke</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>981</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr70-1559827612460499">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennel</surname><given-names>KA</given-names></name>
<name><surname>Drake</surname><given-names>MT</given-names></name>
<name><surname>Hurley</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Vitamin D deficiency in adults: when to test and how to treat</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>:<fpage>752</fpage>-<lpage>757</lpage>.</citation>
</ref>
<ref id="bibr71-1559827612460499">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>AC</given-names></name>
<name><surname>Manson</surname><given-names>JE</given-names></name>
<name><surname>Abrams</surname><given-names>SA</given-names></name><etal/>
</person-group>. <article-title>The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>53</fpage>-<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr72-1559827612460499">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Norval</surname><given-names>M</given-names></name>
<name><surname>Wulf</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Does chronic sunscreen use reduce vitamin D production to insufficient levels?</article-title> <source>Br J Dermatol</source>. <year>2009</year>;<volume>161</volume>:<fpage>732</fpage>-<lpage>736</lpage>.</citation>
</ref>
<ref id="bibr73-1559827612460499">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bech-Thomsen</surname><given-names>N</given-names></name>
<name><surname>Wulf</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Sunbathers’ application of sunscreen is probably inadequate to obtain the sun protection factor assigned to the preparation</article-title>. <source>Photodermatol Photoimmunol Photomed</source>. <year>1992</year>;<volume>9</volume>:<fpage>242</fpage>-<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr74-1559827612460499">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buller</surname><given-names>DB</given-names></name>
<name><surname>Andersen</surname><given-names>PA</given-names></name>
<name><surname>Walkosz</surname><given-names>BJ</given-names></name><etal/>
</person-group>. <article-title>Compliance with sunscreen advice in a survey of adults engaged in outdoor winter recreation at high-elevation ski areas</article-title>. <source>J Am Acad Dermatol</source>. <year>2012</year>;<volume>66</volume>:<fpage>63</fpage>-<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr75-1559827612460499">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Robinson</surname><given-names>JK</given-names></name>
<name><surname>Rigel</surname><given-names>DS</given-names></name>
<name><surname>Amonette</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Summertime sun protection used by adults for their children</article-title>. <source>J Am Acad Dermatol</source>. <year>2000</year>;<volume>42</volume>(<issue>5, pt 1</issue>):<fpage>746</fpage>-<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr76-1559827612460499">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aloia</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Clinical review: The 2011 report on dietary reference intake for vitamin D: where do we go from here?</article-title> <source>J Clin Endocrinol Metab</source>. <year>2011</year>;<volume>96</volume>:<fpage>2987</fpage>-<lpage>2996</lpage>.</citation>
</ref>
<ref id="bibr77-1559827612460499">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SQ</given-names></name>
<name><surname>Lim</surname><given-names>HW</given-names></name>
</person-group>. <article-title>Current status of the sunscreen regulation in the United States: 2011 Food and Drug Administration’s final rule on labeling and effectiveness testing</article-title>. <source>J Am Acad Dermatol</source>. <year>2011</year>;<volume>65</volume>:<fpage>863</fpage>-<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr78-1559827612460499">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sambandan</surname><given-names>DR</given-names></name>
<name><surname>Ratner</surname><given-names>D</given-names></name>
</person-group>. <article-title>Sunscreens: an overview and update</article-title>. <source>J Am Acad Dermatol</source>. <year>2011</year>;<volume>64</volume>:<fpage>748</fpage>-<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr79-1559827612460499">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinnell</surname><given-names>SR</given-names></name>
<name><surname>Fairhurst</surname><given-names>D</given-names></name>
<name><surname>Gillies</surname><given-names>R</given-names></name>
<name><surname>Mitchnick</surname><given-names>MA</given-names></name>
<name><surname>Kollias</surname><given-names>N</given-names></name>
</person-group>. <article-title>Microfine zinc oxide is a superior sunscreen ingredient to microfine titanium dioxide</article-title>. <source>Dermatol Surg</source>. <year>2000</year>;<volume>26</volume>:<fpage>309</fpage>-<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr80-1559827612460499">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitchnick</surname><given-names>MA</given-names></name>
<name><surname>Fairhurst</surname><given-names>D</given-names></name>
<name><surname>Pinnell</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Microfine zinc oxide (Z-cote) as a photostable UVA/UVB sunblock agent</article-title>. <source>J Am Acad Dermatol</source>. <year>1999</year>;<volume>40</volume>:<fpage>85</fpage>-<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr81-1559827612460499">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newman</surname><given-names>MD</given-names></name>
<name><surname>Stotland</surname><given-names>M</given-names></name>
<name><surname>Ellis</surname><given-names>JI</given-names></name>
</person-group>. <article-title>The safety of nanosized particles in titanium dioxide- and zinc oxide-based sunscreens</article-title>. <source>J Am Acad Dermatol</source>. <year>2009</year>;<volume>61</volume>:<fpage>685</fpage>-<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr82-1559827612460499">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burnett</surname><given-names>ME</given-names></name>
<name><surname>Wang</surname><given-names>SQ</given-names></name>
</person-group>. <article-title>Current sunscreen controversies: a critical review</article-title>. <source>Photodermatol Photoimmunol Photomed</source>. <year>2011</year>;<volume>27</volume>:<fpage>58</fpage>-<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr83-1559827612460499">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wakefield</surname><given-names>G</given-names></name>
<name><surname>Lipscomb</surname><given-names>S</given-names></name>
<name><surname>Holland</surname><given-names>E</given-names></name>
<name><surname>Knowland</surname><given-names>J</given-names></name>
</person-group>. <article-title>The effects of manganese doping on UVA absorption and free radical generation of micronised titanium dioxide and its consequences for the photostability of UVA absorbing organic sunscreen components</article-title>. <source>Photochem Photobiol Sci</source>. <year>2004</year>;<volume>3</volume>:<fpage>648</fpage>-<lpage>652</lpage>.</citation>
</ref>
<ref id="bibr84-1559827612460499">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsuji</surname><given-names>JS</given-names></name>
<name><surname>Maynard</surname><given-names>AD</given-names></name>
<name><surname>Howard</surname><given-names>PC</given-names></name><etal/>
</person-group>. <article-title>Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles</article-title>. <source>Toxicol Sci</source>. <year>2006</year>;<volume>89</volume>:<fpage>42</fpage>-<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr85-1559827612460499">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SQ</given-names></name>
<name><surname>Stanfield</surname><given-names>JW</given-names></name>
<name><surname>Osterwalder</surname><given-names>U</given-names></name>
</person-group>. <article-title>In vitro assessments of UVA protection by popular sunscreens available in the United States</article-title>. <source>J Am Acad Dermatol</source>. <year>2008</year>;<volume>59</volume>:<fpage>934</fpage>-<lpage>942</lpage>.</citation>
</ref>
<ref id="bibr86-1559827612460499">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forestier</surname><given-names>S</given-names></name>
</person-group>. <article-title>Rationale for sunscreen development</article-title>. <source>J Am Acad Dermatol</source>. <year>2008</year>;<volume>58</volume>(<issue>5</issue> <supplement>suppl 2</supplement>):<fpage>S133</fpage>-<lpage>S138</lpage>.</citation>
</ref>
<ref id="bibr87-1559827612460499">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SQ</given-names></name>
<name><surname>Burnett</surname><given-names>ME</given-names></name>
<name><surname>Lim</surname><given-names>HW</given-names></name>
</person-group>. <article-title>Safety of oxybenzone: putting numbers into perspective</article-title>. <source>Arch Dermatol</source>. <year>2011</year>;<volume>147</volume>:<fpage>865</fpage>-<lpage>866</lpage>.</citation>
</ref>
<ref id="bibr88-1559827612460499">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schlumpf</surname><given-names>M</given-names></name>
<name><surname>Cotton</surname><given-names>B</given-names></name>
<name><surname>Conscience</surname><given-names>M</given-names></name>
<name><surname>Haller</surname><given-names>V</given-names></name>
<name><surname>Steinmann</surname><given-names>B</given-names></name>
<name><surname>Lichtensteiger</surname><given-names>W</given-names></name>
</person-group>. <article-title>In vitro and in vivo estrogenicity of UV screens</article-title>. <source>Environ Health Perspect</source>. <year>2001</year>;<volume>109</volume>:<fpage>239</fpage>-<lpage>244</lpage>.</citation>
</ref>
<ref id="bibr89-1559827612460499">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayden</surname><given-names>CG</given-names></name>
<name><surname>Roberts</surname><given-names>MS</given-names></name>
<name><surname>Benson</surname><given-names>HA</given-names></name>
</person-group>. <article-title>Systemic absorption of sunscreen after topical application</article-title>. <source>Lancet</source>. <year>1997</year>;<volume>350</volume>:<fpage>863</fpage>-<lpage>864</lpage>.</citation>
</ref>
<ref id="bibr90-1559827612460499">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ou-Yang</surname><given-names>H</given-names></name>
<name><surname>Stanfield</surname><given-names>J</given-names></name>
<name><surname>Cole</surname><given-names>C</given-names></name>
<name><surname>Appa</surname><given-names>Y</given-names></name>
<name><surname>Rigel</surname><given-names>D</given-names></name>
</person-group>. <article-title>High-SPF sunscreens (SPF ≥ 70) may provide ultraviolet protection above minimal recommended levels by adequately compensating for lower sunscreen user application amounts</article-title> [published online March 29, 2012]. <source>J Am Acad Dermatol</source>. doi:<pub-id pub-id-type="doi">10.1016/j.jaad.2012.02.029.</pub-id></citation>
</ref>
<ref id="bibr91-1559827612460499">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osterwalder</surname><given-names>U</given-names></name>
<name><surname>Herzog</surname><given-names>B</given-names></name>
</person-group>. <article-title>Sun protection factors: worldwide confusion</article-title>. <source>Br J Dermatol</source>. <year>2009</year>;<volume>161</volume>(<supplement>suppl 3</supplement>):<fpage>13</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr92-1559827612460499">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paller</surname><given-names>AS</given-names></name>
<name><surname>Hawk</surname><given-names>JL</given-names></name>
<name><surname>Honig</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>New insights about infant and toddler skin: implications for sun protection</article-title>. <source>Pediatrics</source>. <year>2011</year>;<volume>128</volume>:<fpage>92</fpage>-<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr93-1559827612460499">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hornung</surname><given-names>RL</given-names></name>
<name><surname>Hansen</surname><given-names>LA</given-names></name>
<name><surname>Sharp</surname><given-names>LK</given-names></name>
<name><surname>Poorsattar</surname><given-names>SP</given-names></name>
<name><surname>Lipsky</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Skin cancer prevention in the primary care setting: assessment using a standardized patient</article-title>. <source>Pediatr Dermatol</source>. <year>2007</year>;<volume>24</volume>:<fpage>108</fpage>-<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr94-1559827612460499">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SQ</given-names></name>
<name><surname>Kopf</surname><given-names>AW</given-names></name>
<name><surname>Marx</surname><given-names>J</given-names></name>
<name><surname>Bogdan</surname><given-names>A</given-names></name>
<name><surname>Polsky</surname><given-names>D</given-names></name>
<name><surname>Bart</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Reduction of ultraviolet transmission through cotton T-shirt fabrics with low ultraviolet protection by various laundering methods and dyeing: clinical implications</article-title>. <source>J Am Acad Dermatol</source>. <year>2001</year>;<volume>44</volume>:<fpage>767</fpage>-<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr95-1559827612460499">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoffmann</surname><given-names>K</given-names></name>
<name><surname>Laperre</surname><given-names>J</given-names></name>
<name><surname>Avermaete</surname><given-names>A</given-names></name>
<name><surname>Altmeyer</surname><given-names>P</given-names></name>
<name><surname>Gambichler</surname><given-names>T</given-names></name>
</person-group>. <article-title>Defined UV protection by apparel textiles</article-title>. <source>Arch Dermatol</source>. <year>2001</year>;<volume>137</volume>:<fpage>1089</fpage>-<lpage>1094</lpage>.</citation>
</ref>
<ref id="bibr96-1559827612460499">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hatch</surname><given-names>KL</given-names></name>
<name><surname>Osterwalder</surname><given-names>U</given-names></name>
</person-group>. <article-title>Garments as solar ultraviolet radiation screening materials</article-title>. <source>Dermatol Clin</source>. <year>2006</year>;<volume>24</volume>:<fpage>85</fpage>-<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr97-1559827612460499">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osterwalder</surname><given-names>U</given-names></name>
<name><surname>Rohwer</surname><given-names>H</given-names></name>
</person-group>. <article-title>Improving UV protection by clothing: recent developments</article-title>. <source>Recent Results Cancer Res</source>. <year>2002</year>;<volume>160</volume>:<fpage>62</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr98-1559827612460499">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucas</surname><given-names>RM</given-names></name>
</person-group>. <article-title>An epidemiological perspective of ultraviolet exposure: public health concerns</article-title>. <source>Eye Contact Lens</source>. <year>2011</year>;<volume>37</volume>:<fpage>168</fpage>-<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr99-1559827612460499">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>SQ</given-names></name>
<name><surname>Balagula</surname><given-names>Y</given-names></name>
<name><surname>Osterwalder</surname><given-names>U</given-names></name>
</person-group>. <article-title>Photoprotection: a review of the current and future technologies</article-title>. <source>Dermatol Ther</source>. <year>2010</year>;<volume>23</volume>:<fpage>31</fpage>-<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr100-1559827612460499">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walsh</surname><given-names>JE</given-names></name>
<name><surname>Bergmanson</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Does the eye benefit from wearing ultraviolet-blocking contact lenses?</article-title> <source>Eye Contact Lens</source>. <year>2011</year>;<volume>37</volume>:<fpage>267</fpage>-<lpage>272</lpage>.</citation>
</ref>
<ref id="bibr101-1559827612460499">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>JA</given-names></name>
<name><surname>Sorace</surname><given-names>M</given-names></name>
<name><surname>Spencer</surname><given-names>J</given-names></name>
<name><surname>Siegel</surname><given-names>DM</given-names></name>
</person-group>. <article-title>The indoor UV tanning industry: a review of skin cancer risk, health benefit claims, and regulation</article-title>. <source>J Am Acad Dermatol</source>. <year>2005</year>;<volume>53</volume>:<fpage>1038</fpage>-<lpage>1044</lpage>.</citation>
</ref>
<ref id="bibr102-1559827612460499">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>S</given-names></name>
<name><surname>Kramer</surname><given-names>H</given-names></name>
</person-group>. <article-title>Who uses sunbeds? A systematic literature review of risk groups in developed countries</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2010</year>;<volume>24</volume>:<fpage>639</fpage>-<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr103-1559827612460499">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christenson</surname><given-names>LJ</given-names></name>
<name><surname>Borrowman</surname><given-names>TA</given-names></name>
<name><surname>Vachon</surname><given-names>CM</given-names></name><etal/>
</person-group>. <article-title>Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>294</volume>:<fpage>681</fpage>-<lpage>690</lpage>.</citation>
</ref>
<ref id="bibr104-1559827612460499">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reed</surname><given-names>KB</given-names></name>
<name><surname>Brewer</surname><given-names>JD</given-names></name>
<name><surname>Lohse</surname><given-names>CM</given-names></name>
<name><surname>Bringe</surname><given-names>KE</given-names></name>
<name><surname>Pruitt</surname><given-names>CN</given-names></name>
<name><surname>Gibson</surname><given-names>LE</given-names></name>
</person-group>. <article-title>Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota</article-title>. <source>Mayo Clin Proc</source>. <year>2012</year>;<volume>87</volume>:<fpage>328</fpage>-<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr105-1559827612460499">
<label>105.</label>
<citation citation-type="journal">
<collab>International Agency for Research on Cancer Working Group on Artificial Ultraviolet (UV) Light and Skin Cancer</collab>. <article-title>The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review</article-title>. <source>Int J Cancer</source>. <year>2007</year>;<volume>120</volume>:<fpage>1116</fpage>-<lpage>1122</lpage>.</citation>
</ref>
<ref id="bibr106-1559827612460499">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karagas</surname><given-names>MR</given-names></name>
<name><surname>Stannard</surname><given-names>VA</given-names></name>
<name><surname>Mott</surname><given-names>LA</given-names></name>
<name><surname>Slattery</surname><given-names>MJ</given-names></name>
<name><surname>Spencer</surname><given-names>SK</given-names></name>
<name><surname>Weinstock</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Use of tanning devices and risk of basal cell and squamous cell skin cancers</article-title>. <source>J Natl Cancer Inst</source>. <year>2002</year>;<volume>94</volume>:<fpage>224</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr107-1559827612460499">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>HW</given-names></name>
<name><surname>James</surname><given-names>WD</given-names></name>
<name><surname>Rigel</surname><given-names>DS</given-names></name>
<name><surname>Maloney</surname><given-names>ME</given-names></name>
<name><surname>Spencer</surname><given-names>JM</given-names></name>
<name><surname>Bhushan</surname><given-names>R</given-names></name>
</person-group>. <article-title>Adverse effects of ultraviolet radiation from the use of indoor tanning equipment: time to ban the tan</article-title>. <source>J Am Acad Dermatol</source>. <year>2011</year>;<volume>64</volume>:<fpage>893</fpage>-<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr108-1559827612460499">
<label>108.</label>
<citation citation-type="web">
<collab>National Conference of State Legislatures</collab>. <article-title>Tanning restrictions for minors, a state-by-state comparison</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.ncsl.org/issues-research/health/indoor-tanning-restrictions-for-minors.aspx">http://www.ncsl.org/issues-research/health/indoor-tanning-restrictions-for-minors.aspx</ext-link>. <access-date>Accessed May 10, 2012</access-date>.</citation>
</ref>
<ref id="bibr109-1559827612460499">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hornung</surname><given-names>RL</given-names></name>
<name><surname>Magee</surname><given-names>KH</given-names></name>
<name><surname>Lee</surname><given-names>WJ</given-names></name>
<name><surname>Hansen</surname><given-names>LA</given-names></name>
<name><surname>Hsieh</surname><given-names>YC</given-names></name>
</person-group>. <article-title>Tanning facility use: are we exceeding Food and Drug Administration limits?</article-title> <source>J Am Acad Dermatol</source>. <year>2003</year>;<volume>49</volume>:<fpage>655</fpage>-<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr110-1559827612460499">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levins</surname><given-names>PC</given-names></name>
<name><surname>Carr</surname><given-names>DB</given-names></name>
<name><surname>Fisher</surname><given-names>JE</given-names></name>
<name><surname>Momtaz</surname><given-names>K</given-names></name>
<name><surname>Parrish</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Plasma beta-endorphin and beta-lipoprotein response to ultraviolet radiation</article-title>. <source>Lancet</source>. <year>1983</year>;<volume>2</volume>:<fpage>166</fpage>.</citation>
</ref>
<ref id="bibr111-1559827612460499">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>M</given-names></name>
<name><surname>Liguori</surname><given-names>A</given-names></name>
<name><surname>Lang</surname><given-names>W</given-names></name>
<name><surname>Rapp</surname><given-names>SR</given-names></name>
<name><surname>Fleischer</surname><given-names>AB</given-names><suffix>Jr</suffix></name>
<name><surname>Feldman</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners</article-title>. <source>J Am Acad Dermatol</source>. <year>2006</year>;<volume>54</volume>:<fpage>709</fpage>-<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr112-1559827612460499">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosher</surname><given-names>CE</given-names></name>
<name><surname>Danoff-Burg</surname><given-names>S</given-names></name>
</person-group>. <article-title>Addiction to indoor tanning: relation to anxiety, depression, and substance use</article-title>. <source>Arch Dermatol</source>. <year>2010</year>;<volume>146</volume>:<fpage>412</fpage>-<lpage>417</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>